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ABSTRACT: UDP and UDP-glucose activate the P2Y14 receptor
(P2Y14R) to modulate processes related to inflammation, diabetes, and
asthma. A computational pipeline suggested alternatives to naphthalene of
a previously reported P2Y14R antagonist (3, PPTN) using docking and
molecular dynamics simulations on a hP2Y14R homology model based on
P2Y12R structures. By reevaluating the binding of 3 to P2Y14R
computationally, two alternatives, i.e., alkynyl and triazolyl derivatives,
were identified. Improved synthesis of fluorescent antagonist 4 enabled
affinity quantification (IC50s, nM) using flow cytometry of P2Y14R-
expressing CHO cells. p-F3C-phenyl-triazole 65 (32) was more potent
than a corresponding alkyne 11. Thus, additional triazolyl derivatives
were prepared, as guided by docking simulations, with nonpolar aryl
substituents favored. Although triazoles were less potent than 3 (6),
simpler synthesis facilitated further structural optimization. Additionally,
relative P2Y14R affinities agreed with predicted binding of alkynyl and triazole analogues. These triazoles, designed through a
structure-based approach, can be assessed in disease models.
■ INTRODUCTION
Extracellular uridine-5′-diphosphate (1) and uridine-5′-diphos-
phoglucose (2, Chart 1) activate the P2Y14 receptor (P2Y14R), a
G protein-coupled receptor (GPCR) belonging to the
rhodopsin-like δ-branch, to modulate cell functions related to
inflammation, diabetes, asthma, and other diseases.1,2 This
receptor subtype is a member of the P2Y12R-like subfamily of
nucleotide receptors, which inhibit the production of 3′,5′-cyclic
adenosine monophosphate (cAMP) through Gi protein. The
P2Y14R promotes hypersensitivity in microglial cells,
3 the
mobility of neutrophils,4 the release of mediators from mast
cells,5 inflammation in renal intercalated cells,6 and mixed effects
in insulin function.7,8 Thus, approaches to novel antagonists of
nucleotide signaling at the P2Y14R would be desirable for
exploration as novel therapeutics. The P2Y14R is also present in
the CNS, where it suppresses release of matrix metal-
loproteinase-9 (MMP-9) and tumor necrosis factor (TNF)
from astrocytes.9
Only a limited set of P2Y14R antagonists are currently known.
Several chemotypes based on naphthoic acid and pyrido[4,3-
d]pyrimidine were reported originally in patents to provide
potent P2Y14R antagonists, which however displayed low oral
bioavailability.10−13 One of those naphthoic acid derivatives, 4-
(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-
naphthoic acid (PPTN, 3), was profiled pharmacologically at the
entire family of eight P2YRs and found to display high affinity
and selectivity (IC50 = 0.4 nM at P2Y14R and >10 μM at other
P2YR subtypes).14 We demonstrated that the piperidine group
of 3 was a suitable site for chemical derivatization and chain
extension to prepare high affinity fluorescent probes of the
P2Y14R. This conclusion was supported by molecular modeling
and ligand docking, which showed the piperidine ring facing
outward at the surface of the receptor.15 One such probe, 4,
displayed exceptionally high affinity and low nonspecific binding
when used as a tracer in a flow cytometric assay of the P2Y14R in
whole Chinese hamster ovary (CHO) cells expressing the
receptor.
Although previous approaches to modeling of P2YRs were
subject to high uncertainty, we now have appropriate templates
to obtain detailed docking predictions and structural explan-
ations of previously determined structure−activity relationship
(SAR) within the P2Y12R-like subfamily, e.g., uracil nucleotides
binding to the P2Y14R.
16 In the present study, a human (h)
P2Y14R homology model based on recent hP2Y12R X-ray
structures17,18 served as a template to conduct docking and
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molecular dynamics (MD) simulations. The immediate goal was
to suggest bioisosteric alternatives to the hydrophobic and
unwieldy naphthalene ring of 3 that would maintain a similar
orientation of the piperidine and 4-(trifluoromethyl)-phenyl
substituents when bound to the receptor and therefore preserve
receptor affinity. We sought to simultaneously reduce the
molecular weight and avoid the high lipophilicity of 3 that
contributes to its low solubility and difficulty of purification.13
■ RESULTS
The macromolecular starting point of our study is a previously
obtained hP2Y14R MD-refined homology model based on the
agonist-bound hP2Y12R X-ray structure (PDB ID: 4PXZ).
16−18
The reference antagonist structure 3 (PPTN) has been docked
into the model by using an Induced Fit Docking (IFD) protocol
(see Methods section), and the complex has been refined by
subjecting it to 10 ns of membraneMD simulations. With respect
to the starting agonist-bound hP2Y14R homology model
(Supporting Information, Figure S1A),16 the refined structure
used in this study (Supporting Information, Figure S1B) featured
a larger binding cavity extending toward the extracellular side.
The adaptation of the binding site to the antagonist structure
caused a rearrangement of the position of transmembrane
domain (TM)2 and TM7 with respect to the TM bundle
(Supporting Information, Figure S2A): in particular, TM7 was
pushed outward, whereas the axis of TM2 became slightly bent
toward TM3. Moreover, the extension of the binding site region
toward the extracellular side reoriented the first and second
extracellular loops (ECL1 and ECL2, respectively) away from the
TM bundle (Supporting Information, Figure S2B,C). Notably,
Chart 1. Agonist and Antagonist Ligand Probes of the P2Y14R
a
aEndogenous agonists 1 and 2 have functional EC50 values at the hP2Y14R of 160 and 261 nM, respectively.
45 Antagonist 3 is highly potent at the
hP2Y14R (KB from Schild analysis = 0.434 nM)
14 but suffers from adverse physicochemical properties (highly hydrophobic/amphipathic) that make
dissolution and purification difficult. Fluorescent antagonist 4 is highly potent at the hP2Y14R (functional Ki = 0.080 nM).
15.
Figure 1. Workflow of the computational pipeline. Selection of naphthalene bioisosteres was guided by a previous study focused on A3AR agonists.
Between the two proposed alternatives, the triazole analogue resulted as being the most promising according to membrane MD simulations analysis of
the ligand−protein complexes as compared with the reference compound. Consequently, a small library of 57 triazole analogues was designed and
docked inside the hP2Y14R. Poses were selected by visual inspection. The synthesis and experimental validation of the compounds were prioritized
according to the overlap between compounds functional groups and protein interaction sites.
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the differences described above in the MD refined agonist- and
antagonist-bound hP2Y14R homology models mirror those
experimentally observed for the hP2Y12R X-ray structures.
17,18
Therefore, the final hP2Y14R MD-refined structure (Supporting
Information) has been used as a template for all subsequent
docking simulations.
Starting from this refined template, we developed a computa-
tional pipeline comprising three subsequent phases (Figure 1):
(i) bioisostere search, (ii) compound screening, and (iii) hit
selection. The bioisostere search stage envisaged the use of
docking runs followed by 30 ns of MD simulations to identify
linking groups as suitable replacements of half of the naphthalene
ring while preserving the ligand−receptor interactions observed
for the reference compound. The selection of the linkers has
been mainly guided by the knowledge gained in a previous study
that led to the design of highly potent A3 adenosine receptor
(A3AR) agonists.
19 Once a new scaffold was found, a small library
of hypothetical compounds was screened by means of docking
simulations. Pose filtering and hit selection were based upon
ligand−receptor complementarity and optimal overlap between
ligand functional groups and computed protein interaction sites.
In the first instance, the parent structure 3 was redocked into
the MD-refined model. The corresponding pose (Figure 2A)
showed an overall root-mean-square deviation (RMSD) value
with respect to the final MD snapshot of 0.42 Å (data not
shown). In the predicted binding mode, the ligand resided in the
orthosteric binding site in an orientation similar to that
previously reported for hP2Y14R antagonist probes:
15 the 2-
naphthoic acid carboxylate bridged Lys772.60 (according to
conventional TM numbering20), Lys2777.35, and Tyr1023.33,
while the piperidine group pointed outward with the nitrogen
atom establishing a H-bond interaction with the backbone of
Gly802.63. The docking pose has been subjected to 30 ns of
membrane MD simulation, and the RMSD with respect to the
starting structure has been computed (Figure 2B, magenta line);
this analysis served as a confirmation of the docking pose stability
as well as a reference to compare newly proposed compounds
containing bioisosteres of the naphthalene. During the MD
simulation, compound 3 exhibited an average RMSD of 3.76 Å
that can be ascribed mainly to motion of the solvent-exposed
piperidine ring. As shown in the trajectory visualization
(Supporting Information, Video S1), the naphthalene core
with its carboxylate group is well anchored in the binding site
during the 30 ns time frame by a tight H-bond network
established with Lys772.60, Lys2777.35, and Tyr1023.33. However,
the distal piperidine nitrogen suddenly moved apart from the
pose predicted by docking and approached the backbone of
Figure 2. (A) Docking pose of reference compound 3 (magenta-colored carbons) at hP2Y14R. (B) RMSD plots for the considered compounds during
30 ns of membrane MD simulations. (C) Docking pose of the alkynyl derivative 11 (orange-colored carbons) at hP2Y14R. (D) Docking pose of the
triazolyl derivative 65 (green-colored carbons) at the hP2Y14R. Side chains of residues important for ligand recognition are reported as sticks (dark-cyan
carbon atoms). Side chains of residues establishing either van der Waals or hydrophobic contacts with the ligand are rendered as transparent surface. H-
Bonds are pictured as green solid lines, whereas π−π stacking interactions as cyan dashed lines with the centroids of the aromatic rings displayed as cyan
spheres. Nonpolar hydrogen atoms are omitted.
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Ile170 in the second extracellular loop (EL2) through the
interplay of water molecules.
The first proposed alternative structure was an alkyne
derivative (11, Scheme 1) containing a p-CF3-phenyl group,
similar to 3. The compound was docked into the MD-refined
hP2Y14R homology model and then subjected to 30 ns of MD
simulations. In the resulting pose (Figure 2C), the trifluor-
omethylphenyl group was buried in a deep hydrophobic pocket,
and the carboxylate group interacted with Lys772.60, Tyr1023.33,
and Lys2777.35 as in the docking pose of 3 (Figure 2A). Although
during the MD simulations of the hP2Y14−11 complex, the
ligand atoms displayed an average RMSD value (3.79 Å) close to
the one observed for the reference compound, the corresponding
graph suggested that compound 11 was less stable than 3 in the
binding pocket (Figure 2B, orange and magenta lines,
respectively). In particular, in the first 15 ns of simulation,
compound 11 experienced an increasing deviation from the
starting pose, leading to a higher root-mean-square fluctuation
(RMSF = 1.52 vs 1.16 Å for compounds 11 and 3, respectively).
The trajectory analysis (Supporting Information, Video S2)
revealed that, after a few ns, the piperidine ring of derivative 11
moved from the docking pose to establish an H-bond interaction
with the backbone of Ile170 EL2 and Gln169EL2 in a way similar to
that observed for the reference compound. On the other hand,
after approximately 12 ns, the side chain of Tyr1023.33 moved to
engage the trifluoromethylphenyl group in a T-shaped π−π
stacking interaction. This movement caused a weakening of the
H-bond network around the carboxylate moiety of 11 that
increased the number of water molecules surrounding the group
during the trajectory.
On the basis of the analogy observed for the docking poses and
trajectory analyses of compound 11 with respect to the reference
structure 3, we synthesized 11 using both Sonogashira21 and
Suzuki22 cross-coupling reactions (Scheme 1). In particular, a
Sonogashira coupling reaction of a iodo arene 5b with 4-
(trifluoromethyl)phenylacetylene (6) in the presence of tetrakis-
(triphenylphosphine)palladium yielded derivative 7. Compound
5b was obtained by esterification of a commercial precursor 5a.
The 3-hydroxy group of 7 was then converted to the
corresponding aryl triflate 8 using triflic anhydride and pyridine.
A Suzuki cross-coupling reaction between 8 and dioxaborolane
derivative 9, prepared by conventional Suzuki−Miyaura
reaction23 in the presence of tetrakis(triphenylphosphine)-
palladium catalyst, afforded compound 10. Finally, removal of
the N-Boc protecting group followed by hydrolysis of the ester
provided derivative 11. This route would allow a wide variety of
substitutions to be introduced at a late stage in the synthetic
sequence because of the commercial availability of numerous
arylacetylene derivatives.
On the basis of the suggestion that the replacement of the
naphthoic acid core of 3 with an alkynyl group might lead to the
loss of an anchoring hydrogen bond with Tyr1023.33, other
alternatives were considered as well. A similarly versatile
synthetic approach could be used for introducing arylacetylene
moieties in the form of 1,2,3-triazoles by copper-catalyzed [2 + 3]
cycloaddition24 with an azido group present on the core of the
molecule. The corresponding triazole derivative containing a p-
CF3-phenyl group (65, Scheme 2) was subjected to the same
computational protocol described for compound 11 (docking
followed by 30 ns of MD simulations). The resulting docking
pose (Figure 2D) suggested a placement of compound 65 in the
binding site similar to that predicted for 3 and 11, which
encompassed a tight H-bond network around the carboxylate
group with the piperidine ring solvent-exposed. On the other
side, a slightly higher placement within the binding site enabled
compound 65 to establish an additional π−π stacking interaction
with the side chain of His1845.36, while the piperidine ring was
anchored by an H-bond with the Ile167EL2 backbone.
MD simulations of the hP2Y14−65 complex resulted in lower
average RMSD and RMSF values of 3.48 and 0.70 Å, respectively
(Figure 2B, dark-green line). After a few ns (Supporting
Information, Video S3), the ligand moved deeper in the binding
site and was stabilized by persistent π−π stacking interactions
established between the triazole group and Tyr1023.33 and
Scheme 1. Synthesis of an Alkynyl Derivative 11 as a P2Y14R Antagonist
a
aReagents and conditions: (a) CH3OH, SOCl2, 0−23 °C (33%); (b) 1-ethynyl-4-(trifluoromethyl)benzene, CuI, PdCl2(PPh3)2, DMF, NEt3, 0−23
°C (81%); (c) (CF3SO2)2O, NEt3, CH2Cl2 (98%); (d) tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine-1-carboxylate,
Pd(PPh3)4, K2CO3, DMF (67%); (e) LiOH (aqueous 0.5M), CH3OH reflux, then HCl (1 M aq), pH 1 (28%).
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between the trifluoromethylphenyl group and His1845.36. A π−
cation interaction between the triazole ring and the side chain of
Arg2536.55 further contributed to stabilizing the ligand position
during the 30 ns time frame. Conversely to what was observed for
compounds 3 and 11, the piperidine ring moved toward
Gly802.63. The carboxylate group of 65 maintained a stable
position, and the water molecules surrounding the carboxylate
group of 11 were not observed during the simulation of the
hP2Y14−65 complex.
On the basis of these favorable predictions, using a strategy
similar to Scheme 1, triazolyl derivative 65 and its analogues were
synthesized starting from the 3-amino-5-bromobenzoic acid
(12) and 4-(4-bromophenyl)piperidin-4-ol (16, Scheme 2). The
carboxylic group of 12 was first converted to the methyl ester 13,
and then the amine function was protected to give Boc-derivative
14. The palladium-catalyzed condensation of aryl bromide 14
with bis(pinacolato)-diboron under basic conditions afforded
dioxaborolane 15. The acid-catalyzed dehydration of 16 yielded
alkene 17, which was reduced to provide compound 18.
Derivative 19 was obtained by coupling 18 with compound 15
under Suzuki conditions.22 The conversion of the amino group of
19 to a trifluoroacetamide 20 was accomplished using trifluoro-
acetic anhydride in the presence of triethylamine. Removing the
N-Boc protecting group of 20 gave the amine 21. Compound 21
was converted into aryl azide 22 from an arenediazonium tosylate
that was generated in situ and subsequent addition of sodium
azide.25 The protected 1,2,3-triazolyl derivatives 23−63 were
synthesized via an azide−alkyne Huisgen cycloaddition (“click
Scheme 2. Synthesis of Triazolyl Derivatives as P2Y14R Antagonists
a
aReagents and conditions: (a) CH3OH, SOCl2, 0−23 °C (98%); (b) Boc2O, DMAP, CH2Cl2; (c) PdCl2(dppf), AcOK, DMF, 95 °C (74%); (d)
F3CCO2H, 90 °C (97%); (e) H2, Rh/C, 100 psi (98%); (f) Pd(Ph3P)4, K2CO3, DME, 85 °C (71%); (g) (CF3CO)2O, NEt3, Et2O; (h) F3CCO2H,
CH2Cl2 (70%); (i) (1) Ts-OH, NaNO2, H2O/acetonitrile, (2) NaN3, (83%); (j) CuSO4, sodium ascorbate (1 M aq); (k) KOH (1 M aq). R is
defined in Tables 1 and 2.
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Scheme 3a
aReagents and conditions: (A) (a) TsCl, NEt3, DMAP, CH2Cl2, rt 15 h (88%); (b) LiBr, DMF, rt, 12 h (82%); (c) HBr 48% soln, 80 °C, 20 h
(61%); (d) NaN3, H2O, reflux, 12 h (80%); (e) SOCl2, EtOH, 0 °C to rt (78%); (f) K2CO3, DMF (92%); (g) CuSO4 (15 mol %), sodium ascorbate
(45 mol %), t-BuOH:H2O:CH2Cl2 (51%); (h) LiOH (aqueous 0.5 M), CH3OH reflux, then HCl (1 M aq), pH 1 (21%). (B) (a) (1) TSTU, N,N-
diisopropylethylamine, DMF, (2) LiOH, 0.5 M, MeOH:H2O; (b) TSTU, N,N-diisopropylethylamine, DMF; (c) DMF, water, 0 °C.
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reaction”) involving aryl azide 22, various alkynes, Cu(II)sulfate
salt, and sodium ascorbate.26 One-pot hydrolysis of the
trifluoroacetamide and the ester in the presence of KOH yielded
compounds 64−104, which were purified by semiprep HPLC
and isolated either as acetate or triethylammonium salts.
The synthesis of fluorescent antagonist 4 as previously
reported15 suffered from a low yield in the final click
cycloaddition step to link the azide-functionalized fluorophore
and the alkyne-functionalized pharmacophore. Given the
unusually high affinity of 4 and its low nonspecific character,
we explored an alternate synthesis of 4. This was necessary to
provide a sufficient supply of fluorescent probe 4 for use in
routine assays, which we needed for the new putative antagonists
11 and 64−104. A more efficient route consisted of forming an
amide as the ultimate or penultimate step. Thus, the
pharmacophore was functionalized with an extended amine
through a preformed triazole linker to provide intermediate 113
(Scheme 3A). The coupling of AlexaFluor488 fluorophore27 and
pharmacophore was attempted by two methods, either: (1)
condensation of the fluorophore as a 5-carboxylic acid 115 to the
ethyl ester-protected derivative 113 of the pharmacophore
followed by ester saponification, or (2) by reaction of the
fluorophore that was activated in situ as a N-succinimidyl ester
116 with the amino derivative 114, having a deprotected
carboxylic acid (Scheme 3B). However, only the second
synthetic route provided compound 4 and at the same time
improved the reaction yield compared to the previous synthetic
method.15 Furthermore, we explored a different fluorescent
antagonist analogue for possible use in screening, e.g., 130
containing a cyanine-5 (Cy5) fluorophore, but this compound
was considerably less potent at the hP2Y14R in comparison to 4
(Supporting Information).
Alkyne derivative 11 was tested in a functional assay of
antagonism of the agonist-induced inhibition of cAMP
production in the presence of 30 μM forskolin in Chinese
hamster ovary (CHO-K1) cells stably expressing the hP2Y14R
(P2Y14R-CHO cells, using an EC80 concentration of agonist 2 of
316 nM).14 Under these conditions, the IC50 values for 11 was
5690 ± 1440 (n = 3). Thus, this alkyne derivative was shown to
be an antagonist with considerably less affinity than reference
antagonist 3.
Although the alkyne 11 was not deemed a high priority lead
compound because of its moderate potency, the triazoles
achieved higher affinity. Compound 65 and the other newly
synthesized triazole derivatives were assayed in a flow cytometry
competition assay using whole cells (P2Y14R-CHO), and
fluorescent antagonist ligand 4 (20 nM) as a tracer. Figure 3A
shows typical flow cytometry traces in the presence of
representative triazole inhibitors at a single concentration. The
antagonist affinities of the various analogues were compared by
this method, first by screening at a relatively high single
concentration of inhibitor (3 μM) to identify the most potent
analogues. The reference compound 65 inhibited fluorescent
labeling by 92%; thus, it appeared to be a suitable highly potent
lead compound for exploring the SAR in this series. Those IC50
values of triazole analogues inhibiting the fluorescent labeling by
80% or greater were determined in full concentration−response
curves, which were sigmoidal, as shown for representative
compounds in Figure 3B.
Selection of favored terminal aryl groups in the triazole series,
other than 4-F3C-Ph (65), was based on predictions arising from
the docking of a library of 57 hypothetical triazole derivatives
(Supporting Information, Table S1), which could be easily
synthesized by the same route as for 65. The criteria underlying
the hit selection are reported in Table 1 and are based upon
ligand−receptor complementarity and overlap of scaffold
functional groups with computed receptor interaction sites
(Supporting Information, Table S2). Initially, selected entries
66−75 were synthesized for testing using the fluorescent
hP2Y14R assay. On the basis of the SAR determined for the
initial set, a second group of P2Y14R antagonists 76−104 was
prepared (Table 2) and evaluated similarly for the ability to
inhibit fluorescent binding at the hP2Y14R.
The compounds that at 3 μM displayed inhibition of >80% of
the fluorescent ligand (4, 20 nM) binding to the P2Y14R tended
Figure 3. Biological characterization of triazole derivatives. Flow
cytometric analysis (A) of the binding of selected triazolyl derivatives in
comparison to reference naphthoic acid derivative 3 at the P2Y14R
expressed in CHO cells, as detected through inhibition of fluorescent
cell labeling with 4. Concentration−response curves for selected
compounds (B) displayed a smooth concentration dependence of the
inhibition. The IC50 values are given in Table 3. (C) Effects of P2Y14R
antagonist 65 on cAMP levels in P2Y14R-expressing CHO cells.
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to be phenyl derivatives with 4-CF3 (65), 4-Cl (70), 4-Br (71), 4-
n-Pr (77), 4-i-Pr (78), 4-t-Bu (79), 4-n-pentyl-O (82), 4-OCF3
(84), and 3,4-F2 (90) substituents. Also, a 5-bromothien-2-yl
derivative (75) nearly completely inhibited P2Y14R fluorescent
labeling. The compounds that displayed inhibition of 60%−80%
contained a thien-3-yl (72) or 5-chlorothien-2-yl group (74) or
were phenyl derivatives with 4-C2H5 (66), 4-CH3 (76), 4-t-Bu
(79), 3-CF3 (80), 3-OCF3 (85), 4-F (87), 3,5-diF (91), 4-
COCH3 (94), and benzofuran-2-yl (101) substituents. Among
the weakest compounds, with <20% inhibition were 4-CH2OH
(67), 2-OCH3 (83), 3-OH (96), and 3-NH2 (97) phenyl
analogues and pyridyl (98), pyrazinyl (99), and thiazolyl (102)
analogues. Both unsubstituted phenyl analogue 64 and the
cyclohexyl analogue 103 inhibited P2Y14R binding in the
intermediate range. Thus, recognizable patterns of SAR were:
polar groups, H-bond donor groups, and heteroatom (especially
N) substitution of an aryl ring were not well tolerated, while
nonpolar phenyl substituents and especially para-substitution of
the phenyl ring were favored.
The IC50 values of the compounds that were examined in the
fluorescent assay with full concentration−response curves are
given in Table 3. The IC50 values of the reference naphthoic acid
3 was 6.0 nM, and the values for 10 triazoles ranged from 31.7
nM (65) to 481 nM (78). The potencies were in the rank order
of: 3 > 65 > 77 > 75 > 71, 82, 84 > 79, 90, 76, 70 > 78.
The most potently binding triazole derivative 65 was shown in
measurements of cAMP to be an antagonist at the P2Y14R
expressed in CHO cells, similar to known and potent antagonist
3 (Figure 3C). P2Y14R agonist 2 (1 μM) was applied in the
absence or presence of antagonist 3 (1 μM) or compound 65 (1
μM) to cells stimulated with 30 μM forskolin. As expected,
compound 2 significantly decreased forskolin-induced cAMP
levels, but in the presence of either compound 3 or 65, P2Y14R
agonist 2 did not inhibit cAMP accumulation. We also studied
the effect of compound 65 on calcium mobilization induced by
several other P2YRs. 65 (up to 10 μM) was inactive as either
agonist or antagonist at the hP2Y1R and hP2Y6R expressed in
1321N1 astocytoma cells (Supporting Information, Figure S4).
Compounds 11, 65, and 74 were separately evaluated by the
Psychoactive Drug Screening Program (PDSP)28 at various
P2YRs and found to be inactive (10 μM) as agonist or antagonist
at human P2Y1, P2Y2, P2Y4, and P2Y11Rs (calcium transients)
expressed in 1321N1 astrocytoma cells and protease-activated
receptor (PAR)1 expressed in mouse KOLF cells.
Off-target activities for selected compounds were measured by
the PDSP.28 Compounds 3 and 11 each showed only a few off-
target interactions at <10 μM. At these sites, the measured Ki
values (μM) of 3 were 6.79 (D3 dopamine receptor) and 2.75 (δ-
opioid receptor), and the Ki values (μM) of 11 were 1.46 (σ1
receptor) and 3.60 (σ2 receptor). All other receptors, channels,
and transporters in the standard diverse screen of the PDSP were
not significant (i.e., <50% binding inhibition at 10 μM). A
representative triazole derivative (74) showed no off-target
interactions, but the trifluoromethyl analogue (65) bound
weakly (Ki, μm) at H1 histamine (0.17) and α2A (1.56) and
α2C (1.32) adrenergic receptors. Thus, only a few off-target
interactions were detected in these chemical series.
■ DISCUSSION
The aim of this project was the synthesis of a library of novel
triazole-based structures as possible antagonists of the P2Y14R
having improved physicochemical properties. A triazole moiety
was proposed as an alternative bioisosteric replacement for the
Table 1. Selection of Terminal Aryl Group Based on Docking
and Molecular Dynamics Simulation of Various Triazole
Derivativesc
aPercent inhibition at 3 μM of binding of fluorescent antagonist 4 (20
nM) in P2Y14R-CHO cells (n = 3). NS, not synthesized.
bStructure in
Chart 1. cAll ligands were docked to a 10 ns molecular dynamics
refined 3-bound P2Y14R homology model.
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naphthoic acid core of the potent P2Y14R antagonist 3. On the
basis of the results previously achieved with the same
substitutions for A3AR agonists,
19 alkyne derivatives and triazole
derivatives were considered for components of the core to mimic
the favorable interactions present in the naphthoic acid series. By
docking to a homology model of the receptor, the envisaged
structures were predicted to occupy the same binding site within
the P2Y14R as 3, maintaining a similar orientation of the
Table 2. Second Group of Triazolyl P2Y14R Antagonists That Was Prepared Based on Expanding the SAR Found in Table 1
aPercent inhibition at 3 μM of binding of fluorescent antagonist 4 (20 nM) in P2Y14R-CHO cells
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piperidine and 4-(trifluoromethyl)-phenyl substituents within
the ligand binding pocket and preserving the affinity. Docking
and MD simulation have suggested that the triazole scaffold can
form additional interactions that stabilize the ligand within the
receptor binding pocket. A p-CF3-phenyl group bearing triazole
(65) proved to be of higher affinity than the corresponding
alkyne (11); thus, the triazoles were explored in detail.
The synthetic route to the triazole series was versatile to allow
the introduction of a wide range of functional groups on a
terminal aryl substituent late in the synthesis. Both Suzuki and
click cycloaddition reactions were applied sequentially to a
benzoic ester moiety. The triazole derivatives were prepared by a
late-stage diversification strategy, introducing the 1,2,3-triazole
moiety at the end of the synthetic sequence by a copper-catalyzed
[2 + 3] cycloaddition between an azide moiety and various
arylacetylene derivatives. The choice of arylacetylene derivatives
was initially guided by docking andMD studies. The overall yield
from aniline 12 to protected azide 22 was 15%, with the last two
steps (click reaction and deprotection) of variable, but usually
high yield. One unexpected result was the hydrolysis of the 3-
cyanophenyl group during the last deprotection step to a 3-
carboxyphenyl group (92).
These new compounds were assayed in a convenient flow
cytometric fluorescence competition assay with our previously
reported antagonist probe 4 in P2Y14R-CHO cells, confirming
the general docking predictions. Moreover, the expanded SAR
exploration (Table 2) provided greater insight. The terminal aryl
group attached to the triazole required hydrophobic substitution
for high affinity, as the unsubstituted phenyl analogue (64) was
weak in P2Y14R binding. The general preference for substitution
of a phenyl ring at this position was p- > m- ≥ o-, as evidenced
with the methoxy analogues (81 > 68 ≥ 83) and the fluoro
analogues (87 > 88≈ 89). Similarly, there was a preference for p-
over m- substitution in trifluoromethyl (65 > 80) and
trifluoromethoxy (84 > 85) analogues. Thus, there is a
hydrophobic pocket that tolerates considerable steric bulk, e.g.,
the 4-tert-butyl analogue (79), in this region of the receptor, as
predicted in ligand docking to the P2Y14R homology model.
However, introducing polar groups to form predicted H-bonding
interactions with specific groups surrounding this aryl ring failed
to enhance affinity. This trend could be explained by the
observation that a residue side chain (Ser1875.39) that was
predicted in the docking simulation to form H-bonds with the
ligand polar groups was not available for ligand interaction when
analyzed in the dynamic context of the membrane-embedded
solvated receptor (data not shown). The most potent
compounds, with IC50 values ranging from 32 to 131 nM, had
substituents: 4-CF3-ϕ 65 > 4-n-propyl-ϕ 77 > 5-Br-thienyl 75 >
4-Br-ϕ 71, 4-n-pentyloxy-ϕ 82, and 4-CF3O-ϕ 84. Substitution
of the 4-CF3 group of 65 with 4-CH3 in 76 considerably lowered
the affinity 7-fold (IC50 237 nM). These affinities were not as
potent as reference compound 4 (IC50 6.0 nM) in the same assay.
The lead molecule 3 is a highly selective antagonist of the
P2Y14R;
14 although selectivity of these antagonists with respect
to P2Y12R and P2Y13R remains to be determined, several
derivatives were shown to be inactive at all P2Y1-like receptors.
The physicochemical properties of the triazole derivatives
remain to be determined experimentally. However, an online
tool for calculating small-molecule pharmacokinetic and toxicity
properties predicted some advantage; 3 (2.7 μM solubility
predicted) would be 100% bound to human plasma protein and
65 (6.9 μM solubility predicted) would be 1.5% unbound.29 The
triazole ring benefited from increased polarity and additional H-
bond accepting groups compared to the naphthalene core of 3.
The cLogP of 3 is 5.65, which is more hydrophobic than the
optimal range of ∼2−4, while the corresponding triazole
derivative 65 had a cLogP of 4.59. The halogen substitution of
a potent 3,4-difluorophenyl analogue 90might impede potential
oxidation by CYP450 enzymes in the liver.
■ CONCLUSION
In conclusion, we have used structural insights to discover a new
scaffold 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl) for P2Y14R
antagonists. The high affinity among members of this chemical
series of triazole derivatives provides new tools to aid in our
understanding of P2Y14R pharmacology and potentially could
lead to clinically useful drug candidates for inflammatory,
endocrine, and other conditions.
■ EXPERIMENTAL SECTION
Chemical Synthesis. Reagents and Instrumentation. The proton
and carbon nuclear magnetic resonance spectra were recorded using
Bruker 400 MHz, Bruker 500, or Bruker 600 NMR spectrometer.
Purification of final compounds was performed by preparative HPLC
(column: Luna 5 μm C18(2) 100 Å, LC column 250 mm × 4.6 mm).
Method A: eluent 0.1% TFA in water−CH3CN from 100:0 to 70:30 in
45 min with a flow rate of 5 mL/min. Method B: eluent 10 mM
triethyammonium acetate buffer−CH3CN from 80:20 to 20:80 in 40
min, then 10mM triethyammonium acetate buffer−CH3CN from 20:80
to 0:100 in 10 min with a flow rate of 5 mL/min. Purities of all tested
compounds were ≥95%, as estimated by analytical HPLC (column:
Zorbax SB-Aq 5 μm analytical column, 150 mm × 4.6 mm; Agilent
Technologies, Inc.). Method: eluent 5 mM triethyammonium
phosphate monobasic solution−CH3CN from 90:10 to 0:100 in 20
min, then triethyammonium phosphate monobasic solution−CH3CN
from 0:100 to 90:10 in 5 min with a flow rate of 1 mL/min. Peaks were
detected by UV absorption (254 nm) using a diode array detector. All
derivatives tested for biological activity showed >95% purity in the
HPLC system. Analytical thin-layer chromatography was carried out on
Sigma-Aldrich TLC plates, and compounds were visualized with UV
light at 254 nm. Silica gel flash chromatography was performed using
230−400 mesh silica gel. Unless noted otherwise, reagents and solvents
were purchased from Sigma-Aldrich (St. Louis, MO). Compound 3 was
synthesized as reported.14 Low-resolution mass spectrometry was
performed with a JEOL SX102 spectrometer with 6 kV Xe atoms
following desorption from a glycerol matrix or on an Agilent LC/MS
1100 MSD, with a Waters (Milford, MA) Atlantis C18 column. High-
Table 3. Potencies of P2Y14R Antagonists in Flow Cytometry
Assay Determined with Full Concentration−Response
Curves
compd P2Y14R potency, IC50 (nM)
a
3 6.0 ± 0.1
65 31.7 ± 8.0
70 290 ± 88
71 115 ± 15
75 91 ± 4
76 237 ± 90
77 72.4 ± 14.0
78 481 ± 81
79 224 ± 64
82 162 ± 25
84 131 ± 39
90 228 ± 63
aPercent inhibition of binding of fluorescent antagonist 4 (20 nM) in
P2Y14R-CHO cells (n = 3), over a concentration range of 10
−9 to 10−5
M.
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resolution mass spectroscopic (HRMS) measurements were performed
on a proteomics optimized Q-TOF-2 (Micromass-Waters) using
external calibration with polyalanine. cLogP was calculated using
ChemDraw Professional (PerkinElmer, Boston, MA, v. 15.0).
6-Amino-9-(2-carboxy-4-((6-(4-(4-(4-(4-(3-carboxy-6-(4-
(trifluoromethyl)phenyl)-naphthalen-1-yl)phenyl)piperidin-1-yl)-
butyl)-1H-1,2,3-triazol-1-yl)hexyl)carbamoyl)-phenyl)-3-iminio-5-
sulfo-3H-xanthene-4-sulfonate (4). To a solution of AlexaFluor 488
115 (4.44 mg, 7.08 μmol) and N,N-diisopropylethylamine (1.34 μL,
7.72 μmol) in dry DMF (400 μL), TSTU (2.42 mg, 7.72 μmol) was
added at 0 °C. The resulting mixture was allowed to warm up at rt and
stirred for 2−3 h. Then, a solution of 114 (4.5 mg, 6.44 μmol) andN,N-
diisopropylethylamine (1.30 μL, 7.08 μmol) in dry DMF (300 μL) was
added, and the reaction was stirred overnight at rt. After removal of the
solvent, the residue was purified by preparative HPLC (method A, Rt =
24.9 min). The product 4 was obtained as an orange solid after
lyophilization (0.8 mg, 10%). MS (ESI, m/z) 1212 [M − H]−. ESI-
HRMS calcd m/z for C62H57F3N2O12S2 1212.3462, found 1212.3459
[M − H]−. HPLC purity 96.1% (Rt = 5.7 min).
4′-(Piperidin-4-yl)-5-((4-(trifluoromethyl)phenyl)ethynyl)-[1,1′-bi-
phenyl]-3-carboxylic Acid Hydrochloride (11). Lithium hydroxide
(aqueous 0.5M, 70 μL, 25 μmol) was added to a solution of 10 (13 mg,
23 μmol) in methanol (0.2 mL), and the mixture was heated at reflux for
1.5 h. During this time, 10 was completely consumed. The mixture was
allowed to cool to 23 °C and acidified with hydrochloric acid (1M) until
pH 1. The acidified mixture was stirred for additional 2 h before solvents
were removed under reduced pressure. The residue was subjected to
column chromatography (silica gel), eluting with chloroform/
methanol/acetic acid 100/10/1 (v/v) mixture. Hydrochloric acid (1
M) was added to fractions containing the product, and the solvent was
removed under reduced pressure to provide the desired product 11 as a
hydrochloride salt (3.1 mg, 28%). MS (ESI, m/z) 450 [M + H]+. 1H
NMR (400 MHz, DMSO-d6): δ (ppm) = 8.24 (s, 1H), 8.11 (t, J = 1.63
Hz, 1H), 8.08 (s, 1H), 7.85 (s, 1H), 7.79 (td, J = 1.51, 7.78 Hz, 1H), 7.73
(td, J = 1.38, 7.53 Hz, 1H), 7.69 (d, J = 8.03 Hz, 2H), 7.41 (t, J = 7.65 Hz,
1H), 7.35 (d, J = 8.28 Hz, 2H), 3.26 (br. s., 2H), 3.10−3.19 (m, 2H),
2.87 (d, J = 12.55 Hz, 3H), 2.42 (dt, J = 2.64, 7.22 Hz, 2H), 2.33 (td, J =
1.79, 3.70 Hz, 1H).
General Procedure A: Click Cycloaddition Reaction. To a solution
of aryl azide (22, 1 equiv) and aryl alkyne (1.5 equiv) in 2 mL of
THF:water (1:1), sodium ascorbate (freshly prepared 1 M aqueous
solution) and CuSO4 (0.5 equiv) were sequentially added. The resulting
reaction was vigorously stirred for 12 h at rt. The reaction mixture was
then concentrated in vacuo and purified by flash chromatography
(hexane:ethyl acetate = 6:4).
Methyl 5-(4-Phenyl-1H-1,2,3-tr iazol-1-yl)-4 ′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (23).
Yellow solid. MS (ESI, m/z) 535 [M + H]+. ESI-HRMS calcd for
C29H26F3N4O3 535.1952, found 535.1957 [M + H]
+.
Methyl 5-(4-(4-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-
(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxy-
late (24). Orange solid 6.9 mg (99%). MS (ESI, m/z) 603 [M + H]+.
ESI-HRMS calcd for C30H25F6N4O3 603.1825, found 603.1831 [M +
H]+.
Methyl 5-(4-(4-(Ethylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (25).
Yellow solid 2.8 mg (43%). MS (ESI, m/z) 563.2 [M + H]+. ESI-
HRMS calcd for C31H30F3N4O3 563.2270, found 563.2274 [M + H]
+.
Methyl 5-(4-(4-(Hydroxymethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-
(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxy-
late (26). Yellow solid 1.6 mg (25%). MS (ESI, m/z) 565.2 [M + H]+.
ESI-HRMS calcd for C30H28F3N4O4 565.2063, found 565.2068 [M +
H]+.
Methyl 5-(4-(3-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (27).
Yellow solid 4 mg (80%). MS (ESI, m/z) 565.1 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 565.2063, found 565.2056 [M + H]
+.
Methyl 5-(4-(4-Aminophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (28).
Yellow solid 1.7 mg (27%). MS (ESI, m/z) 550.2 [M + H]+. ESI-
HRMS calcd for C29H27F3N5O3 550.2066, found 550.2075 [M + H]
+.
Methyl 5-(4-(4-Chlorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (29).
Yellow solid 3.6 mg (55%). MS (ESI, m/z) 569.2 [M + H]+. ESI-
HRMS calcd for C29H25
35ClF3N4O3 569.1567, found 569.1561 [M +
H]+.
Methyl 5-(4-(4-Bromophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl) piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (30).
Yellow solid 3.8 mg (54%). MS (ESI, m/z) 613.1 [M + H]+. ESI-
HRMS calcd for C29H25
79BrF3N4O3 613.1062, found 613.1057 [M +
H]+.
Methyl 5-(4-(Thiophen-3-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (31).
Yellow solid 4.2 mg (67%). MS (ESI, m/z) 541.1 [M + H]+.
Methyl 5-(4-(Thiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (32).
Yellow solid 1.6 mg (26%). MS (ESI, m/z) 541.2 [M + H]+. ESI-
HRMS calcd for C27H24F3N4O3
32S 541.1521, found 541.1523 [M +
H]+.
Methyl 5-(4-(5-Chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)-piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(33). Brown solid. MS (ESI, m/z) 575 [M + H]+. ESI-HRMS calcd for
C27H23F3N4O3SCl 575.1131, found 575.1132 [M + H]
+.
Methyl 5-(4-(5-Bromothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)-piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(34). Orange solid 5.1 mg (72%). MS (ESI, m/z) 619 [M + H]+. ESI-
HRMS calcd for calcd for C27H23F3N4O3S
79Br 619.0626, found
619.0618 [M + H]+.
Methyl 5-(4-(4-Methylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (35).
Yellow solid 4 mg (80%). MS (ESI, m/z) 549.2 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 549.2114, found 549.2119 [M + H]
+.
Methyl 5-(4-(4-Propylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (36).
Yellow solid 5 mg (76%). MS (ESI, m/z) 577.2 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 577.2427, found 577.2421 [M + H]
+.
Methyl 5-(4-(4-Isopropylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(37). Colorless oil 4 mg (60%). MS (ESI, m/z) 577.2 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 577.2427, found 577.2417 [M + H]
+.
Methyl 5-(4-(4-(tert-Butyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(38). Yellow solid 5.5 mg (81%). MS (ESI, m/z) 591.2 [M + H]+. ESI-
HRMS calcd for C33H34F3N4O3 591.2583, found 591.2589 [M + H]
+.
Methyl 5-(4-(3-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-
(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxy-
late (39). Yellow solid 6.15 mg (89%). MS (ESI, m/z) 603.1 [M + H]+.
ESI-HRMS calcd for C30H25F6N4O3 603.1831, found 603.1825 [M +
H]+.
Methyl 5-(4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (40).
Yellow solid 3.2 mg (49%). MS (ESI, m/z) 565.2 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 565.2063, found 565.2062 [M + H]
+.
Methyl 5-(4-(4-(Pentyloxy)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(41). Pale-yellow oil 5.7 mg (81%). MS (ESI,m/z) 621.2 [M +H]+. ESI-
HRMS calcd for C34H36F3N4O4 621.2689, found 621.2687 [M + H]
+.
Methyl 5-(4-(2-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (42).
Yellow solid 6.5 mg (99%). MS (ESI, m/z) 565.1 [M + H]+. ESI-
HRMS calcd for C30H28F3N4O4 565.2063, found 565.2061 [M + H]
+.
Methyl 5-(4-(4-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-
4′-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxy-
late (43). Yellow solid 3.4 mg (48%). MS (ESI, m/z) 619.1 [M + H]+.
ESI-HRMS calcd for C30H25F6N4O4 619.1780, found 619.1784 [M +
H]+.
Methyl 5-(4-(3-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-
4′-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxy-
late (44). Yellow solid 6mg (84%).MS (ESI,m/z) 619.2 [M +H]+. ESI-
HRMS calcd for C30H25F6N4O4 619.1780, found 619.1778 [M + H]
+.
Methyl 5-(4-(3-Chlorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl) piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (45).
Yellow solid 3.5 mg (54%). MS (ESI, m/z) 569.2 [M + H]+. ESI-
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HRMS calcd for C29H25
35ClF3N4O3 569.1567, found 569.1570 [M +
H]+.
Methyl 5-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (46).
Yellow solid 3.9 mg (61%). MS (ESI, m/z) 553.1 [M + H]+. ESI-
HRMS calcd for C29H25F4N4O3 553.1863, found 553.1855 [M + H]
+.
Methyl 5-(4-(3-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (47).
Yellow solid 4.5 mg (77%). MS (ESI, m/z) 553.2 [M + H]+. ESI-
HRMS calcd for C29H25F4N4O3 553.1863, found 553.1872 [M + H]
+.
Methyl 5-(4-(2-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (48).
Yellow solid 4.9 mg (71%). MS (ESI, m/z) 553.2 [M + H]+. ESI-
HRMS calcd for C29H25F4N4O3 553.1863, found 553.1866 [M + H]
+.
Methyl 5-(4-(3,4-Difluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(49). Pale-yellow solid 4.23 mg (65%). MS (ESI, m/z) 571.1 [M + H]+.
ESI-HRMS calcd for C29H24F5N4O3 571.1769, found 571.1758 [M +
H]+.
Methyl 5-(4-(3,5-Difluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(50). Yellow solid 4.2 mg (63%). MS (ESI, m/z) 571.1 [M + H]+. ESI-
HRMS calcd for C29H24F5N4O3 571.1769, found 571.1762 [M + H]
+.
Methyl 5-(4-(4-Cyanophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (51).
Yellow solid 6 mg (94%). MS (ESI, m/z) 560.2 [M + H]+. ESI-
HRMS calcd for C30H25F4N5O3 560.1909, found 560.1913 [M + H]
+.
Methyl 5-(4-(4-Acetylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (53).
Yellow solid 4.45 mg (67%). MS (ESI, m/z) 577.2 [M + H]+. ESI-
HRMS calcd for C31H28F3N4O4 577.2063, found 577.2056 [M + H]
+.
Methyl 5-(4-(3,4-Dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-
(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate
(54). Yellow solid 5.65 mg (83%). MS (ESI, m/z) 595.2 [M + H]+. ESI-
HRMS calcd for C31H30F3N4O5 595.2168, found 595.2173 [M + H]
+.
Methyl 5-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (55).
Yellow solid 5.15 mg (81%). MS (ESI, m/z) 551.2 [M + H]+. ESI-
HRMS calcd for C29H26F3N4O4 551.1906, found 551.1901 [M + H]
+.
Methyl 5-(4-(3-Aminophenyl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (56).
Yellow solid 2.4 mg (38%). MS (ESI, m/z) 550.2 [M + H]+. ESI-
HRMS calcd for C29H27F3N5O3 550.2066, found 550.2056 [M + H]
+.
Methyl 5-(4-(Pyridin-4-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (57).
Yellow solid 2.3 mg (37%). MS (ESI, m/z) 536.2 [M + H]+. ESI-
HRMS calcd for C28H25F3N5O3 536.1909, found 536.1913 [M + H]
+.
Methyl 5-(4-(Pyrazin-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (58).
Yellow solid 3.5 mg (57%).
Methyl 5-(4-(Furan-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (59).
Yellow solid 3 mg (50%). MS (ESI, m/z) 525.1 [M + H]+. ESI-
HRMS calcd for C27H24F3N4O4 525.1750, found 525.1744 [M + H]
+.
Methyl 5-(4-(Benzofuran-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (60).
Brown solid 4 mg (60%). MS (ESI, m/z) 575.2 [M + H]+. ESI-
HRMS calcd for C31H26F3N4O4 575.1906, found 575.1909 [M + H]
+.
Methyl 5-(4-(Thiazol-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (61).
Yellow solid 4.6 mg (74%). MS (ESI, m/z) 542.1 [M + H]+. ESI-
HRMS calcd for C26H23F3N5O3
32S 542.1474, found 542.1465 [M +
H]+.
Methyl 5-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (62).
Yellow solid 5.4 mg (87%). MS (ESI, m/z) 541.2 [M + H]+. ESI-
HRMS calcd for C29H32F3N4O3 541.2427, found 541.2419 [M + H]
+.
Methyl 5-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)-4′-(1-(2,2,2-
trifluoroacetyl)piperidin-4-yl)-[1,1′-biphenyl]-3-carboxylate (63).
Yellow solid 5.7 mg (99%). MS (ESI, m/z) 499.2 [M + H]+. ESI-
HRMS calcd for C26H26F3N4O3 499.1957, found 499.1959 [M + H]
+.
General Procedure B: Deprotection of Piperidine N and Ester
Hydrolysis. To a solution of protected ester (1 equiv) in 2 mL of
MeOH:H2O (1:1), KOH (10 equiv) was added, and the resulting
mixture was heated at 50 °C for 12 h. After removing the solvents under
reduced pressure, the mixture was purified by semipreparative HPLC
(method B).
5-(4-Phenyl-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-biphen-
yl]-3-carboxylic Acid (64). Semipreparative HPLC: method B, Rt = 25.7
min. The product was obtained as a white solid by lyophilization (1.9
mg, 26%). MS (ESI, m/z) 425 [M + H]+. ESI-HRMS calcd for
C26H25N4O2 425.1978, found 425.1980 [M + H]
+. HPLC purity 97%
(Rt = 8.9 min).
1H NMR (400 MHz, MeOD): δ (ppm) = 8.94 (s, 1H),
8.29 (d, J = 8 Hz, 2H), 7.88 (d, J = 8 Hz, 2H), 7.68 (d, J = 8 Hz, 2H),
7.39−7.43 (m, 2H), 7.31−7.35 (m, 3H), 2.90−2.96 (m, 5H), 1.94−1.97
(m, 2H), 1.77−1.80 (m, 2H).
5-(4-(4-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperi-
din-4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (65). Semipreparative
HPLC: method B, Rt = 30.2 min. The product was obtained as a
white salt by lyophilization (0.5 equiv CH3CO2H-salt, 6.01 mg, 99%).
MS (ESI, m/z) 493.1 [M + H]+. ESI-HRMS calcd for C27H24F3N4O2
493.1851, found 493.1853 [M+H]+. HPLC purity 99% (Rt = 12.6 min),
mp 280−288 °C d. 1HNMR (600MHz, DMSO-d6): δ (ppm) = 9.66 (s,
1H), 8.39 (t, J = 1.6 Hz, 1H), 8.28 (t, J = 1.6 Hz, 1H), 8.22 (d, J = 8.1 Hz,
2H), 8.15 (t, J = 1.6 Hz, 1H), 7.88 (d, J = 8.1 Hz, 2H), 7.75 (d, J = 8.3 Hz,
2H), 7.41 (d, J = 8.3 Hz, 2H), 3.20−3.15 (m, 2H), 2.76 (td, J = 3.2, 12.1
Hz, 3H), 1.88 (s, 1.5 Hacetate), 1.77 (qd, J = 4.2, 12.9 Hz, 4H).
13C NMR
(150 MHz, DMSO-d6): δ (ppm) = 167.1, 146.5, 145.9, 143.9, 140.7,
137.1, 136.5, 134.4, 128.4, 128.2, 127.4 (2C), 127.2, 126.9 (2C), 126.0
(2C), 125.9 (2C), 125.2, 121.1, 119.2, 117.9, 55.0, 46.1 (2C), 41.7, 40.0,
33.4 (2C).
5-(4-(4-Ethylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (66). Semipreparative HPLC:
method B, Rt = 27.0 min. The product was obtained as a white solid
by lyophilization (0.5 equiv CH3CO2H-salt, 3.4 mg, 93%). MS (ESI,m/
z) 453.2 [M + H]+, ESI-HRMS calcd for C28H29N4O2 453.2291, found
453.2294 [M + H]+. HPLC purity 98% (Rt = 11.5 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.42 (s, 1H), 8.37 (s, 1H), 8.25 (s, 1H),
8.13 (s, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 7.9 Hz, 2H), 7.41 (d, J
= 7.9 Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 3.20 (d, J = 12.0 Hz, 2H), 2.81−
2.71 (m, 3H), 2.66 (q, J = 7.6 Hz, 2H), 1.90 (s, 1.5Hacetate), 1.85−1.70
(m, 4H), 1.23 (t, J = 7.6 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ
(ppm) = 167.1, 147.3, 143.8, 142.4, 137.8, 137.0, 128.8, 128.4 (2C),
127.9, 127.4 (2C), 126.9 (2C), 125.4 (2C), 125.2, 119.4, 119.0, 117.6,
28.0, 15.5.
5-(4-(4-(Hydroxymethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperi-
din-4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (67). Semipreparative
HPLC: method B, Rt = 23.3 min. The product was obtained as a
white solid by lyophilization (2 equiv CH3CO2H-salt, 1.4 mg, 87%). MS
(ESI, m/z) 455.2 [M + H]+. ESI-HRMS calcd for C27H27N4O3
455.2083, found 455.2081 [M + H]+. HPLC purity 96% (Rt = 8.42
min). 1H NMR (500MHz, DMSO-d6): δ (ppm) = 9.45 (s, 1H), 8.39 (s,
1H), 8.24 (s, 1H), 8.12 (s, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.73 (d, J = 7.8
Hz, 1H), 7.44 (d, J = 7.8 Hz, 2H), 7.37 (d, J = 7.7 Hz, 2H), 4.55 (s, 2H),
3.05 (d, J = 12.0 Hz, 2H), 2.72−2.53 (m, 3H), 1.77−1.51 (m, 10H
(6Hacetate)).
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 176.0
(2Cacetate), 167.8, 147.6, 147.1, 143.9, 142.9, 141, 137.4, 136.9, 129.2,
127.7 (2C), 127.3 (2C), 127.2, 127.2 (2C), 125.4 (2C), 119.9, 119.4,
118.1, 63.0, 46.9 (2C), 42.5, 39.4, 34.4 (2C), 24.7 (2Cacetate).
5-(4-(3-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (68). Semipreparative HPLC:
method B, Rt = 23.2 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 2.4 mg, 67%). MS (ESI,m/z)
455.2 [M + H]+. ESI-HRMS calcd for C27H27N4O3 455.2083, found
455.2083 [M + H]+. HPLC purity 99% (Rt = 10.1 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.52 (s, 1H), 8.42 (s, 1H), 8.33 (s, 1H),
8.19 (s, 1H), 7.78 (d, J = 7.8 Hz, 2H), 7.63−7.52 (m, 1H), 7.42 (m, 3H),
6.95 (d, J = 8.1 Hz, 1H), 6.81 (s, 1H), 3.84 (s, 3H, CH3), 2.90 (m, 3H),
1.91 (m, 4H). Proton signals for 2-CHpiperidine, 6-CHpiperidine and 3-
CHpiperidine, 5-CHpiperidine are hidden under the H2O and DMSO-d6
signals. 13C NMR (500 MHz, DMSO-d6): δ (ppm) = 172.8 (1Cacetate),
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168.7, 160.3, 147.7, 145.9, 141.3, 137.8, 137.3, 132.2, 130.7, 127.9 (2C),
127.5, 127.4 (2C), 120.5, 119.5, 119.1, 118.1, 114.5, 111.0, 55.7 (2C),
44.6 (2C), 30.8, 29.5 9 (1Cacetate).
5-(4-(4-Aminophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (69). Semipreparative HPLC:
method B, Rt = 17.4 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 2.84 mg, 95%). MS (ESI, m/
z) 440.2 [M + H]+. ESI-HRMS calcd for C26H26N5O2 440.2087, found
440.2094 [M + H]+. HPLC purity 96% (Rt = 8.38 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.21 (s, 1H), 8.38 (s, 1H), 8.24 (s, 1H),
8.11 (s, 1H), 7.77 (d, J = 7.9 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 7.43 (d, J
= 7.9 Hz, 2H), 6.95 (d, J = 8.2 Hz, 1H), 5.36 (s, 2HNH2), 3.10 (d, J = 12.0
Hz, 2H), 2.75−2.59 (m, 4H), 1.79 (d, J = 12.0 Hz, 2H), 1.65−1.51 (m,
2H).
5-(4-(4-Chlorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (70). Semipreparative HPLC:
method B, Rt = 22.7 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 3.3 mg, 99%). MS (ESI,m/z)
459.2 [M +H]+. ESI-HRMS calcd for C26H24
35ClN4O2 459.1588, found
459.1588 [M + H]+. HPLC purity 98.4% (Rt = 11.4 min), mp 223−227
°C. 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.49 (s, 1H), 8.34 (s,
1H), 8.24 (s, 1H), 8.10 (s, 1H), 8.01 (d, J = 8.6 Hz, 2H), 7.72 (d, J = 8.4
Hz, 2H), 7.58 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 3.08 (d, J =
12.2 Hz, 2H), 2.69−2.59 (m, 3H), 1.81−1.70 (m, (3Hacetate), 5H), 1.60
(qd, J = 3.8, 12.4 Hz, 2H). 13C NMR (500MHz, DMSO-d6): δ (ppm) =
173.6 (1Cacetate), 167.6, 145.0, 146.6, 144.2, 141.1 (2C), 137.5, 136.9,
133.0, 129.7, 129.5 (2C), 127.8 (2C), 127.5 (2C), 127.3 (2C), 120.6,
119.6, 118.3, 49.0, 46.5 (2C), 42.2, 33.9 (2C), 23.6 (1Cacetate).
5-(4-(4-Bromophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (71). Semipreparative HPLC:
method B, Rt = 24.2 min. The product was obtained as a white acetate
salt by lyophilization (1 equiv CH3CO2H-salt, 3.5 mg, 99%). MS (ESI,
m/z) 503.1 [M + H]+. ESI-HRMS calcd for C26H24N4O2
79Br 503.1083,
found 503.1080 [M + H]+. HPLC purity 98.4% (Rt = 11.4 min).
1H
NMR (500MHz, DMSO-d6): δ (ppm) = 9.53 (s, 1H), 8.35 (s, 1H), 8.22
(s, 1H), 8.10 (s, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 7.9 Hz, 4H),
7.38 (d, J = 7.9 Hz, 2H), 3.08 (d, J = 12.0 Hz, 2H), 2.72−2.60 (m, 3H),
1.84 (s, 3Hacetate), 1.76 (d, J = 12.0 Hz, 2H), 1.60 (qd, J = 3.8, 12.4 Hz,
2H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.3 (1Cacetate),
167.6, 147.3, 146.9, 144.9, 141.3, 137.9, 137.2, 132.7 (2C), 130.4, 128.1
(2C), 128.0 (2C), 127.7, 127.5 (2C), 121.9, 120.9, 119.8, 118.4, 47.0
(2C), 42.6, 34.4 (2C), 22.9 (1Cacetate).
5-(4-(Thiophen-3-yl)-1H-1,2,3-triazol-1-yl)- 4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (72). Semipreparative HPLC:
method B, Rt = 22.3 min. The product was obtained as a white acetate
salt by lyophilization (1 equiv CH3CO2H-salt, 3.77 mg, 99%). MS (ESI,
m/z) 431.1 [M + H]+. ESI-HRMS calcd for C24H23N4O2
32S 431.1542,
found 431.1548 [M + H]+. HPLC purity 99% (Rt = 9.7 min).
1H NMR
(500 MHz, DMSO-d6): δ (ppm) = 9.40 (s, 1H), 8.39 (s, 1H), 8.27 (s,
1H), 8.13 (s, 1H), 8.05−8.01 (m, 1H), 7.77 (d, J = 7.8Hz, 2H), 7.69 (d, J
= 5.0 Hz, 1H), 7.43 (d, J = 7.8 Hz, 2H), 3.11 (d, J = 12.0 Hz, 2H), 2.76−
2.63 (m, 3H), 1.87−1.76 (m, (3Hacetate), 6H), 1.63 (qd, J = 3.8, 12.0 Hz,
2H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.3 (1Cacetate),
166.9, 146.6, 144.3. 143.8, 140.6, 137.2, 136.5, 131.8, 127.4 (2C), 126.9,
126.8 (2C), 125.8, 121.3, 119.5, 119.0, 117.5, 46.5 (2C), 42.1, 33.9 (2C),
23.8 (1Cacetate), 11.8.
5-(4-(Thiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (73). Semipreparative HPLC:
method B, Rt = 21.8 min. The product was obtained as a white acetate
salt by lyophilization (0.5 equiv CH3CO2H-salt, 2.2 mg, 99%). MS (ESI,
m/z) 431.2 [M + H]+. ESI-HRMS calcd for C24H23N4O2
32S 431.1542,
found 431.1538 [M + H]+. HPLC purity 97% (Rt = 8.9 min).
1H NMR
(400 MHz, DMSO-d6): δ (ppm) = 9.42 (s, 1H), 8.40 (s, 1H), 8.33 (s,
1H), 8.24 (d, J = 2.0 Hz, 1H), 7.81 (d, J = 7.9 Hz, 2H), 7.61 (d, J = 5.0
Hz, 1H), 7.56 (d, J = 3.6 Hz, 1H), 7.45 (d, J = 7.9 Hz, 2H), 7.19 (dd, J =
3.6, 5.1 Hz, 1H), 2.89−3.01 (m, 2H), 2.76−2.68 (m, 3H), 2.05−1.85
(m, (1.5Hacetate), 5H).
13C NMR (150 MHz, DMSO-d6): δ (ppm) =
167.5, 145.5, 143.3, 141.8, 137.4, 137.3, 132.8, 128.5, 127.8 (2C), 127.7
(2C), 127.4, 126.4, 125.1, 119.6, 44.1 (2C), 40.5, 39.3, 29.9 (2C), 29.5.
5-(4-(5-Chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-
4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (74). Semipreparative HPLC:
method B, Rt = 28.6 min. The product was obtained as a white solid by
lyophilization (0.5 equiv CH3CO2H-salt, 2.8 mg, 38%). MS (ESI, m/z)
465 [M + H]+. ESI-HRMS calcd for C24H22N4O2SCl 465.1152, found
465.1151 [M + H]+. HPLC purity 98% (Rt = 10.6 min).
1H NMR (400
MHz, DMSO-d6): δ (ppm) = 9.34 (s, 1H), 8.25 (d, J = 2.4 Hz, 1H), 8.19
(s, 1H), 8.02 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.36−7.29 (m,
3H), 7.13 (d, J = 3.8 Hz, 1H), 3.12 (d, J = 12.0 Hz, 2H), 2.76−2.63 (m,
3H), 1.83−1.61 (m, (1Hacetate), 5H).
5-(4-(5-Bromothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-
4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (75). Semipreparative HPLC:
method B, Rt = 27.2 min. The product was obtained as a white solid by
lyophilization (0.5 equiv CH3CO2H-salt, 2.31 mg, 52%). MS (ESI,m/z)
509.1 [M + H]+. ESI-HRMS calcd for C24H22N4O2SBr 509.0647, found
509.0648 [M + H]+. HPLC purity 98% (Rt = 11.8 min), mp 271−275
°C. 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.43 (s, 1H), 8.35 (s,
1H), 8.29 (s, 1H), 8.12 (s, 1H), 7.74 (d, J = 7.9 Hz, 2H), 7.48−7.35 (m,
3H), 7.33−7.27 (m, 1H), 3.23 (d, J = 12.0 Hz, 2H), 2.87−2.71 (m, 3H),
1.96−1.66 (m, (1.5Hacetate), 5H). 13C NMR (125 MHz, DMSO-d6): δ
(ppm) = 173.0, 167.8, 146.5, 142.4, 141.2, 137.6, 136.9, 134.9, 131.9,
127.9 (2C), 127.6, 127.4 (2C), 125.6, 119.8, 119.6, 119.3, 118.6, 111.5,
72.7, 46.0 (2C), 33.3 (2C), 29.2.
5-(4-(4-Methylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (76). Semipreparative HPLC:
method B, Rt = 24.4 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 3.31 mg, 94%). MS (ESI, m/
z) 439.2 [M + H]+. ESI-HRMS calcd for C27H27N4O2 439.2134, found
439.2133 [M + H]+. HPLC purity 99% (Rt = 10.8 min), mp 280−286
°C. 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 9.40 (s, 1H), 8.36 (s,
1H), 8.22 (s, 1H), 8.10 (s, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.72 (d, J = 8.2
Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 3.10 (d, J =
12.4 Hz, 2H), 2.72−2.62 (m, 3H), 2.36 (s, 3H), 1.84 (s, 3Hacetate), 1.81−
1.73 (m, 2H), 1.63 (qd, J = 3.7, 12.4 Hz, 2H). 13C NMR (150 MHz,
DMSO-d6): δ (ppm) = 173.2, 167.5, 147.7, 146.9, 144.5, 141.0, 137.9,
137.6, 137.0, 129.9 (2C), 128.2, 127.8 (2C), 127.3 (2C), 125.7, 119.8,
119.5, 118.1, 46.7 (2C), 42.3, 40.5, 34.1 (2C), 22.8, 21.4.
5-(4-(4-Propylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (77). Semipreparative HPLC:
method B, Rt = 23.7 min. The product was obtained as a white solid
by lyophilization (0.5 equiv CH3CO2H-salt, 4.5 mg, 98%). MS (ESI,m/
z) 467.2 [M + H]+. ESI-HRMS calcd for C29H31N4O2 467.2447, found
467.2454 [M+H]+. HPLC purity 99.5% (Rt = 12.8 min).
1HNMR (600
MHz, DMSO-d6): δ (ppm) = 9.42 (s, 1H), 8.38 (s, 1H), 8.28 (s, 1H),
8.14 (s, 1H), 7.89 (d, J = 8.0 Hz, 2H), 7.76 (d, J = 7.2 Hz, 2H), 7.43 (d, J
= 7.2 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 3.27−3.17 (m, 2H), 2.84−2.75
(m, 3H), 2.61 (t, J = 7.6 Hz, 2H), 1.90 (s, 1Hacetate), 1.87−1.77 (m, 4H),
1.64 (h, J = 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (150 MHz,
DMSO-d6): δ (ppm) = 149.5, 147.2, 142.2, 128.9 (2C), 127.9 (2C),
127.3 (2C), 125.3 (2C), 119.3, 40.0 (2C), 37.0 (2C), 24.0, 13.6.
5-(4-(4-Isopropylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (78). Semipreparative HPLC:
method B, Rt = 18.1 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 3.55 mg, 97%). MS (ESI, m/
z) 467.2 [M + H]+. ESI-HRMS calcd for C29H31N4O2 467.2447, found
467.2440 [M + H]+. HPLC purity 98% (Rt = 12.5 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.48 (s, 1H), 8.42 (s, 1H), 8.29 (s, 1H),
8.17 (s, 1H), 7.96 (d, J = 7.8Hz, 2H), 7.79 (d, J = 7.8Hz, 2H), 7.48−7.40
(m, 4H), 3.18 (d, J = 12.0 Hz, 2H), 3.00 (hept, J = 7.0 Hz, 1H), 2.81−
2.70 (m, 3H), 1.90 (s, 2Hacetate), 1.84 (d, J = 12.0 Hz, 2H), 1.71 (qd, J =
4.0, 12.0 Hz, 2H), 1.30 (d, J = 7.0 Hz, 4H). 13C NMR (125 MHz,
DMSO-d6): δ (ppm) = 172.5 (1Cacetate), 167.1, 148.4, 147.3, 146.4,
143.9, 140.6, 137.2, 136.6, 128.0, 127.4 (2C), 126.9 (4C), 125.4 (2C),
119.4, 119.0, 117.7, 45.9 (2C), 41.6, 39.4, 39.0, 33.3 (2C), 23.8
(1Cacetate), 22.0.
5-(4-(4-(tert-Butyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-
yl)-[1,1′-biphenyl]-3-carboxylic Acid (79). Semipreparative HPLC:
method B, Rt = 31.1 min. The product was obtained as a white solid by
lyophilization (1 equiv CH3CO2H-salt, 5.03 mg, 99%). MS (ESI, m/z)
481.3 [M + H]+. ESI-HRMS calcd for C30H33N4O2 481.2604, found
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481.2597 [M + H]+. HPLC purity 98% (Rt = 12.5 min), mp 298−303
°C. 0.3 Equiv Et3N and 1 equiv CH3CO2H-salt:
1H NMR (600 MHz,
DMSO-d6): δ (ppm) = 9.41 (s, 1H), 8.37 (s, 1H), 8.25 (s, 1H), 8.13 (s,
1H), 7.91 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 7.9 Hz, 2H), 7.52 (d, J = 8.4
Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 3.19 (d, J = 12.1 Hz, 2H), 2.80−2.74
(m, 2H), 2.43 (q, J = 7.1 Hz, (0.3 equiv Et3N), 3H), 1.85 (s, 3Hacetate),
1.85−1.79 (m, 2H), 1.79−1.67 (m, 2H), 1.33 (s, 9H), 0.93 (t, J = 7.1 Hz,
(0.3 equiv Et3N), 3H). 1 Equiv CH3CO2H-salt:
13C NMR (150 MHz,
DMSO-d6): δ (ppm) = 151.1, 147.7, 141.0, 137.8, 137.1, 128.4, 128.1,
127.8 (2C), 127.3, 127.4 (2C), 126.2 (2C), 125.6 (2C), 120.0, 119.8,
119.5, 40.5 (2C), 34.9 (2C), 31.6 (3C).
5-(4-(3-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperi-
din-4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (80). Semipreparative
HPLC: method B, Rt = 27.6 min. The product was obtained as a
white solid by lyophilization (0.5 equiv CH3CO2H-salt, 2.53 mg, 48%).
MS (ESI, m/z) 493.1 [M + H]+. ESI-HRMS calcd for C27H24N4O2F3
493.1851, found 493.1851 [M+H]+. HPLC purity 99% (Rt = 11.8 min),
mp 277−284 °C. 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.70 (s,
1H), 8.41 (s, 1H), 8.32 (s, 2H), 8.28 (s, 1H), 8.16 (s, 1H), 7.79−7.72
(m, 4H), 7.41 (d, J = 7.9 Hz, 2H), 3.20 (d, J = 12.0 Hz, 2H), 2.88−2.68
(m, 3H), 1.99−1.63 (m, (1.5Hacetate), 5H). 13C NMR (125 MHz,
DMSO-d6): δ (ppm) = 172.5, 167.6, 146.1, 145.8, 143.3, 140.8, 137.2,
136.6, 131.5, 130.3, 130.0, 129.8, 129.0, 127.4 (2C), 127.0, 126.9 (2C),
125.9 (q, JC−F = 274Hz, 1C), 124.7, 121.8, 120.8, 119.0, 118.0, 45.7, 45.2
(2C), 40.8, 32.1 (2C), 29.0, 21.8, 11.7.
5-(4-(4-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (81). Semipreparative HPLC:
method B, Rt = 23.0 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 2.14 mg, 73%). MS (ESI, m/
z) 455.2 [M + H]+. ESI-HRMS calcd for C27H27N4O3 455.2083, found
455.2086 [M + H]+. HPLC purity 97% (Rt = 10.1 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.35 (s, 1H), 8.35 (s, 1H), 8.21 (s, 1H),
7.92 (d, J = 8.7 Hz, 2H), 7.72 (d, J = 7.9 Hz, 2H), 7.38 (d, J = 7.9 Hz,
2H), 7.07 (d, J = 8.7 Hz, 2H), 3.82 (s, 3H), 3.07 (d, J = 11.8 Hz, 2H),
2.70−2.57 (m, 3H), 1.84−1.68 (m, (3Hacetate), 5H), 1.58 (qd, J = 4.0,
12.0 Hz, 2H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.8
(1Cacetate), 167.8, 159.9, 147.9, 147.3, 144.7, 141.3, 137.9, 137.3, 128.1
(2C), 127.6 (2C), 127.5, 127.4 (2C), 123.7, 119.7, 119.5, 118.3, 115.1
(2C), 55.9, 47.1 (2C), 42.7, 34.5 (2C), 29.8, 23.6 (1Cacetate).
5-(4-(4-(Pentyloxy)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-
yl)-[1,1′-biphenyl]-3-carboxylic Acid (82). Semipreparative HPLC:
method B, Rt = 34.1 min. The product was obtained as a white solid by
lyophilization (1 equiv CH3CO2H-salt, 5.3 mg, 99%). MS (ESI, m/z)
511.3 [M + H]+. ESI-HRMS calcd for C31H35N4O3 511.2709, found
511.2703 [M + H]+. HPLC purity 99% (Rt = 14.4 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.40 (s, 1H), 8.40 (s, 1H), 8.28 (s, 1H),
8.16 (s, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.79 (d, J = 7.8 Hz, 2H), 7.45 (d, J
= 7.9 Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H), 4.08 (t, J = 6.5 Hz, 2H), 3.20 (d, J
= 11.8 Hz, 2H), 2.83−2.68 (m, 3H), 1.94 (s, 3Hacetate), 1.89−1.78 (m,
4H), 1.77−1.65 (m, 3H), 1.52−1.38 (m, 4H), 0.97 (t, J = 7.2 Hz, 3H).
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 137.0, 126.9 (2C), 126.3
(2C), 126.2 (2C), 120.6 (2C), 119.2, 118.8, 118.0, 114.4, 77.0, 72.3,
67.0, 46.7 (2C), 27.9, 27.2, 21.4, 13.5.
5-(4-(2-Methoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (83). Semipreparative HPLC:
method B, Rt = 23.0 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 3.05 mg, 52%). MS (ESI, m/
z) 455.2 [M + H]+. ESI-HRMS calcd for C27H27N4O3 455.2083, found
455.2086 [M +H]+. HPLC purity 98% (Rt = 10.44 min).
1H NMR (600
MHz, DMSO-d6): δ (ppm) = 9.02 (s, 1H), 8.33 (s, 1H), 8.24 (s, 1H),
8.22 (d, J = 7.5Hz, 1H), 8.10 (s, 1H), 7.74 (d, J = 7.8Hz, 2H), 7.43−7.34
(m, 3H), 7.18 (d, J = 8.3 Hz, 1H), 7.10 (t, J = 7.5 Hz, 1H), 3.98 (s, 3H),
3.14 (d, J = 12.0 Hz, 3H), 2.74−2.67 (m, 3H), 1.86 (s, 3Hacetate), 1.79 (d,
J = 12.0 Hz, 2H), 1.73−1.62 (m, 2H). 13CNMR (150MHz, DMSO-d6):
δ (ppm) = 173.1 (1Cacetate), 167.9, 156.0, 146.7, 143.7, 143.2, 141.1,
137.6, 137.1, 129.7, 127.7 (2C), 127.4 (2C), 127.3, 122.2, 121.0, 120.0,
119.1, 118.9, 111.9, 55.9, 46.3 (2C), 41.9, 40.4, 33.6 (2C), 22.4
(1Cacetate).
5-(4-(4-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(pi-
peridin-4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (84). Semipreparative
HPLC: method B, Rt = 29.8 min. The product was obtained as a white
acetate salt by lyophilization (1 equiv CH3CO2H-salt, 2.63 mg, 84%).
MS (ESI, m/z) 509.2 [M + H]+. ESI-HRMS calcd for C27H24N4O3F3
509.1801, found 509.1817 [M+H]+. HPLC purity 96% (Rt = 12.3 min),
mp 274−280 °C. 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 9.52 (s,
1H), 8.35 (s, 1H), 8.23 (s, 1H), 8.15−8.05 (m, 3H), 7.72 (d, J = 8.0 Hz,
2H), 7.52 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 3.09 (d, J = 12.1
Hz, 2H), 2.71−2.64 (m, 3H), 1.85 (s, 3Hacetate), 1.77 (d, J = 12.1 Hz,
2H), 1.61 (qd, J = 4.0, 12.1 Hz, 2H). 13CNMR (125MHz, DMSO-d6): δ
(ppm) = 167.6, 148.5, 146.9, 146.5, 141.2, 137.7, 137.0, 130.4, 127.9
(2C), 127.7 (2C), 127.6, 127.4 (2C), 122.3 (2C), 122.2 (q, JC−F = 260.4
Hz), 120.9, 119.7, 118.3, 46.5 (2C), 42.1, 40.7, 40.6, 33.7 (2C), 22.4.
5-(4-(3-(Trifluoromethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-4′-(pi-
peridin-4-yl)-[1,1′-biphenyl]-3-carboxylic Acid (85). Semipreparative
HPLC: method B, Rt = 29.2 min. The product was obtained as a white
acetate salt by lyophilization (0.5 equiv CH3CO2H-salt, 3.63 mg, 66%).
MS (ESI, m/z) 509.2 [M + H]+. ESI-HRMS calcd for C27H24N4O3F3
509.1801, found 509.1798 [M+H]+. HPLC purity 98% (Rt = 12.4 min).
1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.63 (s, 1H), 8.40 (s, 1H),
8.30 (s, 1H), 8.15 (t, J = 2.0 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.94 (s,
1H), 7.75 (d, J = 7.9Hz, 2H), 7.65 (t, J = 8.0 Hz, 1H), 7.42 (d, J = 7.9 Hz,
2H), 7.38 (dd, J = 2.4, 8.1 Hz, 1H), 3.24 (d, J = 11.8 Hz, 2H), 2.88−2.75
(m, 3H), 1.88 (s, 1.5Hacetate), 1.86−1.79 (m, 4H). 13C NMR (125 MHz,
DMSO-d6): δ (ppm) = 171.9, 166.6, 148.5, 145.3, 140.2, 136.7, 135.9,
132.2, 130.7, 126.8 (2C), 126.4 (2C), 123.7, 120.2, 120.0, 119.5, 118.8
(q, JC−F = 257.4 Hz), 117.1, 45.1 (2C), 40.7, 32.1 (2C), 21.1.
5-(4-(3-Chlorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (86). Semipreparative HPLC:
method B, Rt = 21.2 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 2.2 mg, 68%). MS (ESI,m/z)
459.2 [M +H]+. ESI-HRMS calcd for C26H24
35ClN4O2 459.1588, found
459.1583 [M + H]+. HPLC purity 98% (Rt = 11.1 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.59 (s, 1H), 8.36 (s, 1H), 8.22 (s, 1H),
8.10 (s, 1H), 8.05 (d, J = 1.9Hz, 1H), 7.71 (d, J = 7.9Hz, 2H), 7.55 (t, J =
7.9 Hz, 1H), 7.45 (dd, J = 2.1, 8.1 Hz, 1H), 7.38 (d, J = 7.9 Hz, 2H), 2.66
(s, 3H), 1.67 (m, (3Hacetate), 7H).
13C NMR (125 MHz, DMSO-d6): δ
(ppm) = 167.1, 146.9, 146.1, 140.8, 137.4, 136.6, 134.0, 132.9, 131.2,
128.1, 127.6 (2C), 127.3 (2C), 127.0, 125.3, 124.0, 120.8, 119.4, 117.7,
46.8, 42.4 (2C), 34.4 (2C), 29.2.
5-(4-(4-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (87). Semipreparative HPLC:
method B, Rt = 20.6 min. The product was obtained as a salt by
lyophilization (0.5 equiv CH3CO2H-salt, 3.06 mg, 99%). MS (ESI,m/z)
443.2 [M + H]+. ESI-HRMS calcd for C26H24FN4O2 443.1883, found
443.1890 [M + H]+. HPLC purity 96% (Rt = 10.8 min).
1H NMR (400
MHz, DMSO-d6): δ (ppm) = 9.46 (s, 1H), 8.36 (s, 1H), 8.23 (s, 1H),
8.10 (s, 1H), 8.06−7.95 (m, 2H), 7.71 (d, J = 7.7 Hz, 2H), 7.40−7.33
(m, 4H), 3.11−3.01 (m, 2H), 2.70−2.57 (m, 3H), 1.75 (m, 4H), 1.63−
1.50 (m, 2H). 13C NMR (150 MHz, DMSO-d6): δ (ppm) = 163.2,
161.2, 147.0, 146.8, 141.1, 137.6, 137.0, 127.8 (2C), 127.5 (2C), 127.3,
120.2, 119.9, 118.2, 116.5 (2C), 116.3 (2C), 72.7, 70.8, 60.7, 46.6, 42.3
(2C), 40.5, 34.2 (2C), 29.4, 20.7.
5-(4-(3-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (88). Semipreparative HPLC:
method B, Rt = 21.5 min. The product was obtained as a white acetate
salt by lyophilization (0.5 equiv CH3CO2H-salt, 3.4 mg, 84%). MS (ESI,
m/z) 443.1 [M + H]+. ESI-HRMS calcd for C26H24FN4O2 443.1883,
found 443.1884 [M + H]+. HPLC purity 98.2% (Rt = 10.5 min).
1H
NMR (500MHz, DMSO-d6): δ (ppm) = 9.57 (s, 1H), 8.37 (s, 1H), 8.27
(s, 1H), 8.13 (s, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.79 (dt, J = 2.6, 10.2 Hz,
1H), 7.75 (d, J = 7.9 Hz, 2H), 7.56 (td, J = 6.0, 8.0 Hz, 1H), 7.41 (d, J =
7.9 Hz, 2H), 7.22 (td, J = 2.6, 8.6 Hz, 1H), 3.19 (d, J = 11.8 Hz, 2H),
2.82−2.69 (m, 3H), 1.89 (s, 1.5Hacetate), 1.86−1.69 (m, 4H). 13C NMR
(125 MHz, DMSO-d6): δ (ppm) = 173.5, 167.5, 163.01 (d, JC−F = 243.6
Hz), 146.8, 146.5, 144.3, 141.0, 137.5, 136.8, 133.2, 133.2, 131.6, 131.5,
127.8 (2C), 127.4 (2C), 127.2, 121.7, 120.9, 119.4, 118.2, 115.3, 115.2,
112.4, 112.2, 46.4 (2C), 42.1, 33.8 (2C), 23.3.
5-(4-(2-Fluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (89). Semipreparative HPLC:
method B, Rt = 24.3 min. The product was obtained as a white salt by
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lyophilization (1 equiv CH3CO2H-salt, 2.64 mg, 60%). MS (ESI, m/z)
443.1 [M + H]+. ESI-HRMS calcd for C26H24FN4O2 443.1883, found
443.1887 [M + H]+. HPLC purity 99% (Rt = 10.4 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.28 (d, J = 3.0 Hz, 1H), 8.42 (s, 1H), 8.29
(s, 1H), 8.27 (td, J = 1.8, 7.6 Hz, 1H), 8.20 (t, J = 2.1Hz, 1H), 7.81 (d, J =
8.0 Hz, 2H), 7.56−7.46 (m, 2H), 7.46−7.40 (m, 3H), 3.16 (d, J = 12.0
Hz, 2H), 2.81−2.69 (m, 3H), 1.91 (s, 3Hacetate), 1.83 (d, J = 12.0 Hz,
2H), 1.69 (qd, J = 6.4, 12.0 Hz, 2H). 13CNMR (125MHz, DMSO-d6): δ
(ppm) = 173.0 (1Cacetate), 167.5, 159.1 (d, JC−F = 248.3 Hz), 146.9,
144.5, 141.3, 141.1, 137.7, 136.9, 130.5 (d, JC−C−F = 8.4 Hz), 128.3,
127.8 (2C), 127.6, 127.5 (2C), 125.5, 122.5 (d, JC−C−F = 10.1 Hz, H),
120.1, 118.7, 118.6, 116.7, 116.6, 46.6 (2C), 42.2, 33.9 (2C), 22.4
(1Cacetate).
5-(4-(3,4-Difluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-
yl)-[1,1′-biphenyl]-3-carboxylic Acid (90). Semipreparative HPLC:
method B, Rt = 21.1 min. The product was obtained as a white solid by
lyophilization (3.85 mg, 99%). MS (ESI, m/z) 461.2 [M + H]+. ESI-
HRMS calcd for C26H24FN4O2 461.1789, found 461.1790 [M + H]
+.
HPLC purity 97% (Rt = 11.31 min).
1H NMR (500MHz, DMSO-d6): δ
(ppm) = 9.55 (s, 1H), 8.38 (s, 1H), 8.34 (s, 1H), 8.16 (s, 1H), 8.00 (ddd,
J = 2.1, 7.8, 11.0 Hz, 1H), 7.87−7.81 (m, 1H), 7.78 (d, J = 7.9 Hz, 2H),
7.60 (dt, J = 8.5, 11.0 Hz, 1H), 7.45 (d, J = 7.8 Hz, 2H), 3.51−3.38 (m,
2H), 2.96−2.82 (m, 3H), 2.03−1.84 (m, 4H). 13C NMR (125 MHz,
DMSO-d6): δ (ppm) = 151.4 (d, JC−F = 245.3 Hz), 148.6, 146.2, 145.9,
143.9, 141.2, 140.6, 137.8, 136.7, 128.6, 127.9 (2C), 127.4 (2C), 122.6,
120.9, 119.5, 118.9 (d, JC−C−F = 17.7 Hz, H), 114.8 (d, JC−C−F = 18.6 Hz,
H), 72.8, 60.7, 45.3, 32.7.
5-(4-(3,5-Difluorophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-
yl)-[1,1′-biphenyl]-3-carboxylic Acid (91). Semipreparative HPLC:
method B, Rt = 22.2 min. The product was obtained as a white salt by
lyophilization (1 equiv CH3CO2H-salt, 1.24 mg, 33%). MS (ESI, m/z)
461.2 [M + H]+. ESI-HRMS calcd for C26H24FN4O2 calcd for
C26H23F2N4O2 461.1789, found 461.1782 [M + H]
+. HPLC purity
99% (Rt = 11.40 min), mp 284−291 °C. 1H NMR (600 MHz, DMSO-
d6): δ (ppm) = 9.61 (s, 1H), 8.34 (q, J = 1.4 Hz, 1H), 8.23 (t, J = 1.4 Hz,
1H), 8.08 (t, J = 1.4 Hz, 1H), 7.75−7.67 (m, 4H), 7.38 (d, J = 8.3 Hz,
2H), 7.27 (tt, J = 2.4, 9.3 Hz, 1H), 3.05 (d, J = 12.3 Hz, 2H), 2.69−2.56
(m, 2H), 1.78 (s, 3Hacetate), 1.75 (d, J = 12.4 Hz, 2H), 1.57 (qd, J = 3.8,
12.3 Hz, 2H). 13C NMR (150 MHz, DMSO-d6): δ (ppm) = 173.4
(1Cacetate), 167.1, 164.2 (d, JC−C−F = 13.5 Hz), 162.6 (d, JC−C−F = 13.3
Hz), 147.2, 145.7, 145.0, 141.6, 141.0, 137.5, 136.7, 134.4 (t, JC−C−F =
10.7 Hz), 127.8 (2C), 127.6, 127.2 (2C), 121.6, 119.5, 117.9, 109.20−
108.17 (m), 103.8 (t, JC−C−F = 25.8 Hz), 47.1, 42.6 (2C), 34.6 (2C).
5-(4-(4-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (92). Semipreparative HPLC:
method B, Rt = 9.4 min. The product was obtained as a white solid by
lyophilization (4.6 mg, 86%). MS (ESI, m/z) 469.2 [M + H]+. ESI-
HRMS calcd for C27H25F2N4O4 469.1876, found 469.1870 [M + H]
+.
HPLC purity 96% (Rt = 9.30 min).
1H NMR (500 MHz, DMSO-d6): δ
(ppm) = 9.52 (s, 1H), 8.40 (s, 1H), 8.25 (s, 1H), 8.14 (s, 1H), 7.98 (q, J
= 8.1 Hz, 4H), 7.77 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 3.23 (d,
J = 12.2 Hz, 2H), 2.84−2.74 (m, 3H), 1.87−1.77 (m, 4H). Et3N-salt:
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.7 (3Ctriethylamine),
168.8, 167.4, 147.9, 145.0, 142.1, 140.9, 137.6, 136.9, 130.4, 129.9 (2C),
127.7 (2C), 127.2 (2C), 124.5 (2C), 119.9, 119.6, 117.9, 47.1 (2C),
42.7, 34.7 (2C), 26.5 (3Ctriethylamine).
5-(4-(3-Carboxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (93). To a solution of aryl azide (22,
5 mg, 11.5 μmol, 1 equiv) and 3-ethynylbenzoic acid (6, R = 3-PhCO2H,
2.5 mg, 17 μmol, 1.5 equiv) in 2 mL of THF:water (1:1), sodium
ascorbate (17 μmol, freshly prepared 1 M aqueous solution, 1.5 equiv),
and CuSO4 (1.4 mg, 6 μmol, 0.5 equiv) were sequentially added. The
resulting reaction was vigorously stirred for 12 h at rt. The reaction
mixture was then concentrated in vacuo and added to a solution of 2 mL
ofMeOH:1.0 MKOH (1:1), and the mixture was heated at 50 °C for 12
h. After removing the solvents under reduced pressure, the mixture was
purified by preparative HPLC (method B, Rt = 10.4 min). The product
was obtained as a white salt by lyophilization (2 Et3N salt, 5.7 mg, 93%).
MS (ESI, m/z) 469.2 [M + H]+. ESI-HRMS calcd for C27H25F2N4O4
469.1876, found 469.1884 [M +H]+. HPLC purity 97% (Rt = 9.32min).
1H NMR (500 MHz, DMSO-d6): δ (ppm) = 9.69 (s, 1H), 8.55 (s, 1H),
8.49 (s, 1H), 8.36 (s, 1H), 8.30 (s, 1H), 8.20 (d, J = 7.8 Hz, 1H), 7.95 (d,
J = 7.8 Hz, 1H), 7.83 (d, J = 7.9Hz, 2H), 7.62 (t, J = 7.8 Hz, 1H), 7.44 (d,
J = 7.9 Hz, 2H), 3.41 (d, J = 12.0 Hz, 2H), 3.07−3.00 (m, 3H), 2.95 (q, J
= 7.4 Hz, 12Htriethylamine), 2.02−1.88 (m, 4H), 1.12 (t, J = 7.3 Hz,
18Htriethylamine).
13C NMR (150 MHz, DMSO-d6): δ (ppm) = 176.8,
173.6 (6Ctriethylamine), 168.8, 167.3, 148.2, 146.9, 144.0, 144.7, 142.5,
140.8, 137.5, 137.0, 129.6, 129.2, 127.9, 127.7 (2C), 127.2 (2C), 127.1,
126.6, 125.6, 119.8, 119.4, 117.8, 98.2, 46.9 (2C), 42.5, 40.5, 34.4 (2C),
24.6 (6Ctriethylamine).
5-(4-(4-Acetylphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (94). Semipreparative HPLC:
method B, Rt = 19.4 min. The product was obtained as a white salt by
lyophilization (1 equiv CH3CO2H-salt, 3.88 mg, 95%). MS (ESI, m/z)
479.2 [M + H]+. ESI-HRMS calcd for C28H27N4O3 467.2083, found
467.2084 [M + H]+. HPLC purity 97% (Rt = 10.4 min).
1H NMR (400
MHz, DMSO-d6): δ (ppm) = 9.56 (s, 1H), 8.34 (s, 1H), 8.24 (s, 1H),
8.10 (m, 5H), 7.73 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 1H), 3.11 (d, J
= 12.3 Hz, 2H), 2.74−2.64 (m, 3H), 2.61 (s, 3H), 1.79 (s, 3Hacetate), 1.63
(q, J = 10.9, 11.7 Hz, 4H). 13C NMR (125MHz, DMSO-d6): δ (ppm) =
198.2, 167.9, 146.8, 143.9, 141.3, 137.5, 136.9, 136.6, 135.2, 129.6 (2C),
129.3 (2C), 127.9, 127.7 (2C), 127.4 (2C), 125.8, 121.5, 119.9, 119.8,
118.9, 118.6, 72.7, 60.7, 46.4 (2C), 41.9, 33.6 (2C), 27.3.
5-(4-(3,4-Dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-
yl)-[1,1′-biphenyl]-3-carboxylic Acid (95). Semipreparative HPLC:
method B, Rt = 13.5 min. The product was obtained as a white salt by
lyophilization (1 equiv CH3CO2H-salt, 5.2 mg, 99%). MS (ESI, m/z)
485.2 [M + H]+. ESI-HRMS calcd for C28H29N4O4 485.2189, found
485.2195 [M + H]+. HPLC purity 97% (Rt = 9.8 min).
1H NMR (600
MHz, DMSO-d6): δ (ppm) = 9.37 (s, 1H), 8.34 (s, 1H), 8.20 (s, 1H),
8.07 (s, 1H), 7.71 (d, J = 7.8 Hz, 2H), 7.58 (d, J = 2.0Hz, 1H), 7.55 (dd, J
= 2.0, 8.2 Hz, 1H), 7.38 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 8.3 Hz, 1H), 3.87
(s, 3H), 3.81 (s, 3H), 3.07 (s, 2H), 2.72−2.56 (m, 3H), 1.86−1.65 (m,
(3Hacetate), 5H), 1.64−1.47 (m, 2H). 13C NMR (150 MHz, DMSO-d6):
δ (ppm) = 173.2 (1Cacetate), 167.0, 149.6, 149.3, 147.8, 147.1, 145.1,
140.9, 137.7, 136.9, 127.8 (2C), 127.3 (2C), 123.7, 119.4, 119.3, 118.2,
117.7, 112.6, 109.6, 56.0, 46.9 (2C), 42.5, 34.5 (2C), 23.7 (1Cacetate).
5-(4-(3-Hydroxyphenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (96). Semipreparative HPLC:
method B, Rt = 17.9 min. The product was obtained as a white salt by
lyophilization (2 equiv CH3CO2H-salt, 4.7 mg, 99%). MS (ESI, m/z)
441.2 [M + H]+. ESI-HRMS calcd for C26H25N4O3 441.1927, found
441.1931 [M + H]+. HPLC purity 96.2% (Rt = 8.7 min).
1H NMR (600
MHz, DMSO-d6): δ (ppm) = 9.37 (s, 1H), 8.35 (t, J = 1.6 Hz, 1H), 8.21
(t, J = 1.5 Hz, 1H), 8.08 (t, J = 2.0 Hz, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.46
(t, J = 2.0Hz, 1H), 7.40−7.33 (m, 3H), 7.27 (t, J = 7.8Hz, 1H), 6.79 (dd,
J = 2.4, 8.0 Hz, 1H), 3.05 (d, J = 11.7 Hz, 2H), 2.69−2.57 (m, 3H), 1.74
(d, J = 11.9 Hz, 2H), 1.68 (s, 6Hacetate), 1.57 (qd, J = 3.8, 12.4 Hz, 2H).
13C NMR (150MHz, DMSO-d6): δ (ppm) = 173.6, 167.2, 158.6, 147.8,
147.1, 144.9, 140.9, 137.6, 136.9, 132.0, 130.4, 127.8 (2C), 127.3 (2C),
127.3, 120.1, 119.5, 117.9, 116.5, 115.7, 112.7, 47.0 (2C), 42.6, 40.5, 34.6
(2C), 24.7.
5-(4-(3-Aminophenyl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (97). Semipreparative HPLC:
method B, Rt = 17.4 min. The product was obtained as a white solid
by lyophilization (2 equiv CH3CO2H-salt, 2.2 mg, 99%). MS (ESI,m/z)
440.2 [M + H]+. ESI-HRMS calcd for C26H26N5O2 440.2087, found
440.2093 [M + H]+. HPLC purity 97% (Rt = 8.9 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.29 (s, 1H), 8.34 (s, 1H), 8.20 (s, 1H),
8.08 (s, 1H), 7.72 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 7.9 Hz, 2H), 7.25 (s,
1H), 7.15−7.04 (m, 2H), 6.57 (d, J = 7.6Hz, 1H), 5.21 (s, 2H), 3.04 (d, J
= 12.0 Hz, 2H), 2.71−2.55 (m, 3H), 1.78−1.63 (m, (6Hacetate), 8H),
1.56 (qd, J = 3.8, 12.0 Hz, 2H). 13C NMR (125 MHz, DMSO-d6): δ
(ppm) = 173.9 (2Cacetate), 167.4, 149.6, 148.4, 147.2, 144.8, 140.9, 137.7,
137.1, 131.4, 129.9, 127.8 (2C), 127.3(2C), 119.8, 119.6, 118.0, 114.3,
113.8, 111.1, 47.1 (2C), 42.7, 34.6 (2C), 24.4 (2Cacetate).
5-(4-(Pyridin-4-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-
biphenyl]-3-carboxylic Acid (98). Semipreparative HPLC: method B,
Rt = 15.7 min. The product was obtained as a white solid by
lyophilization (2 equiv CH3CO2H-salt, 2 mg, 85%). MS (ESI, m/z)
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426.1 [M + H]+. ESI-HRMS calcd for C25H24N5O2 426.1930, found
426.1933 [M + H]+. HPLC purity 97% (Rt = 9.2 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.71 (s, 1H), 8.74−8.66 (m, 2H), 8.36 (s,
1H), 8.23 (s, 1H), 8.11 (t, J = 2.0 Hz, 1H), 7.95 (d, J = 6.0 Hz, 1H), 7.71
(d, J = 8.2 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 3.05 (d, J = 13.0 Hz, 2H),
2.68−2.54 (m, 3H), 1.75−1.68 (m, (6Hacetate), 8H), 1.56 (qd, J = 3.9,
12.3 Hz, 2H). 13C NMR (1256 MHz, DMSO-d6): δ (ppm) = 174.4
(2Cacetate), 167.3, 150.9 (2C), 147.3, 145.4, 144.8, 141.1, 138.1, 137.5,
136.8, 127.9 (2C), 127.7, 127.3 (2C), 122.4, 120.1 (2C), 119.7, 118.3,
70.3, 47.0 (2C), 42.7, 40.3, 34.6 (2C), 24.4 (2Cacetate).
5-(4-(Pyrazin-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-
biphenyl]-3-carboxylic Acid (99). Semipreparative HPLC: method B,
Rt = 16.8 min. The product was obtained as a white solid by
lyophilization (4 equiv CH3CO2H-salt, 2.81 mg, 64%). MS (ESI, m/z)
427.2 [M + H]+. ESI-HRMS calcd for C24H23N6O2 427.1882, found
427.1881 [M + H]+. HPLC purity 98% (Rt = 8.43 min).
1H NMR (500
MHz, DMSO-d6): δ (ppm) = 9.70 (s, 1H), 9.41 (s, 1H), 8.81 (s, 1H),
8.73 (d, J = 2.7 Hz, 1H), 8.45 (s, 1H), 8.30 (s, 1H), 8.22 (d, J = 2.7 Hz,
2H), 7.82 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 7.8 Hz, 2H), 3.10 (d, J = 12.1
Hz, 3H), 2.75−2.60 (m, 3H), 1.80 (d, J = 13.1 Hz, 2H), 1.71−1.57 (m,
(12Hacetate), 14H).
13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.9
(4Cacetate), 167.1, 147.1, 145.8, 145.8, 145.0, 144.8, 144.4, 141.9, 140.9,
137.4, 136.7, 127.7 (2C), 127.6, 127.3 (2C), 123.1, 119.9, 118.3, 46.9
(2C), 42.6, 34.5 (2C), 25.2 (4Cacetate).
5-(4-(Furan-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-bi-
phenyl]-3-carboxylic Acid (100). Semipreparative HPLC: method B, Rt
= 19.8 min. The product was obtained as a white solid by lyophilization
(1 equiv CH3CO2H-salt 2.28mg, 84%).MS (ESI,m/z) 415.2 [M +H]
+.
ESI-HRMS calcd for C24H23N4O3 415.1770, found 415.1767 [M + H]
+.
HPLC purity 98% (Rt = 9.2 min).
1H NMR (500 MHz, DMSO-d6): δ
(ppm) = 9.30 (s, 1H), 8.38 (s, 1H), 8.29 (s, 1H), 8.15 (t, J = 1.9 Hz, 1H),
7.88 (d, J = 1.8 Hz, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz,
2H), 6.97 (d, J = 3.3 Hz, 1H), 6.72 (dd, J = 3.3, 1.9 Hz, 1H), 3.11 (dt, J =
12.3, 2.9 Hz, 2H), 2.82−2.62 (m, 3H), 1.84−1.73 (m, 5H (3Hacetate)),
1.63 (qd, J = 12.6, 4.1 Hz, 2H). 13C NMR (125 MHz, DMSO-d6): δ
(ppm) = 173.6 (1Cacetate), 167.4, 147.1, 146.0, 144.5, 143.5, 141.1, 140.4,
137.5, 136.8, 127.8 (2C), 127.5, 127.4 (2C), 119.8, 119.6, 118.4, 114.9,
112.3, 107.5, 49.1, 46.9 (2C), 42.5, 34.3 (2C), 29.5, 24.0, 22.6 (1Cacetate),
14.5.
5-(4-(Benzofuran-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-
[1,1′-biphenyl]-3-carboxylic Acid (101). Semipreparative HPLC:
method B, Rt = 21.9 min. The product was obtained as a white solid
by lyophilization (1 equiv CH3CO2H-salt, 4.9 mg, 90%). MS (ESI,m/z)
465.2 [M + H]+. ESI-HRMS calcd for C28H25N4O3 465.1927, found
465.1936 [M + H]+. HPLC purity 97% (Rt = 11.4 min).
1H NMR (600
MHz, DMSO-d6): δ (ppm) = 9.54 (s, 1H), 8.40 (s, 1H), 8.26 (s, 1H),
8.16 (s, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.74 (d, J = 7.6 Hz, 1H), 7.66 (d, J
= 8.1 Hz, 1H), 7.43−7.36 (m, 4H), 7.32 (t, J = 7.4 Hz, 1H), 3.10 (d, J =
12.5Hz, 2H), 2.72−2.61 (m, 3H), 1.85 (s, 3Hacetate), 1.77 (d, J = 12.5Hz,
2H), 1.63 (qd, J = 3.4, 12.0, 12.5 Hz, 2H). 13CNMR (150MHz, DMSO-
d6): δ (ppm) = 173.2 (1Cacetate), 167.5, 154.5, 148.3, 146.9, 144.5, 141.0,
139.9, 137.5, 136.7, 128.7, 127.8 (2C), 127.6, 127.4 (2C), 125.3, 123.9,
121.9, 121.3, 119.8, 118.4, 111.6, 103.4, 46.6 (2C), 42.3, 34.0 (2C), 29.5,
22.6 (1Cacetate).
5-(4-(Thiazol-2-yl)-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-
biphenyl]-3-carboxylic Acid (102). Semipreparative HPLC: method B,
Rt = 18.7 min. The product was obtained as a white salt by lyophilization
(2 equiv CH3CO2H-salt, 4.18 mg, 99%). MS (ESI, m/z) 431.2 [M +
H]+. ESI-HRMS calcd for C23H22N5O2
32S 432.1494, found 432.1494
[M + H]+. HPLC purity 96.4% (Rt = 9.1 min).
1H NMR (400 MHz,
DMSO-d6): δ (ppm) = 9.54 (s, 1H), 8.36 (s, 0H), 8.23 (s, 1H), 8.13 (s,
1H), 7.98 (d, J = 3.3 Hz, 1H), 7.83 (d, J = 3.3 Hz, 1H), 7.74 (d, J = 7.9
Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 3.03 (d, J = 12.9 Hz, 2H), 2.72−2.56
(m, 3H), 1.73 (d, J = 12.9 Hz, 2H), 1.66 (s, 6Hacetate), 1.55 (qd, J = 3.1,
10.6, 11.4 Hz, 2H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 173.1
(2Cacetate), 167.5, 158.7, 146.8, 144.4, 144.2, 143.5, 141.1, 137.5, 136.8,
127.8 (2C), 127.7, 127.4 (2C), 121.3, 120.8, 120.1, 118.8, 46.4 (2C),
42.0, 33.6 (2C), 22.7 (2Cacetate).
5-(4-Cyclohexyl-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-bi-
phenyl]-3-carboxylic Acid (103). Semipreparative HPLC: method B, Rt
= 21.2 min. The product was obtained as a white solid by lyophilization
(2 equiv CH3CO2H-salt, 2.65 mg, 55%). MS (ESI, m/z) 431.3 [M +
H]+. ESI-HRMS calcd for C26H31N4O2 431.2447, found 431.2444 [M +
H]+. HPLC purity 97% (Rt = 10.4 min).
1H NMR (500 MHz, DMSO-
d6): δ (ppm) = 8.77 (s, 1H), 8.35 (s, 1H), 8.25 (s, 1H), 8.09 (s, 1H), 7.76
(d, J = 7.8 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 3.14 (d, J = 11.9 Hz, 2H),
2.85−2.78 (m, 1H), 2.76−2.68 (m, 3H), 2.10 (d, J = 12.3 Hz, 2H),
2.00−1.72 (m, (6Hacetate), 10H), 1.72−1.59 (m, 2H), 1.57−1.26 (m,
6H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 168.2, 153.7, 147.0,
143.7, 141.0, 137.6, 137.3, 127.8 (2C), 127.3 (2C), 127.0, 119.7, 119.5,
118.3, 46.8 (2C), 42.4, 35.2, 34.2 (2C), 33.0 (2C), 26.2, 26.1 (2C), 23.37
(2Cacetate).
5-(4-Cyclopropyl-1H-1,2,3-triazol-1-yl)-4′-(piperidin-4-yl)-[1,1′-bi-
phenyl]-3-carboxylic Acid (104). Semipreparative HPLC: method B, Rt
= 12.6 min. The product was obtained as a white solid by lyophilization
(2 equiv CH3CO2H-salt, 5.1 mg, 87%). MS (ESI,m/z) 389.2 [M +H]
+.
ESI-HRMS calcd for C23H25N4O2 389.1978, found 389.1971 [M + H]
+.
HPLC purity 97% (Rt = 8.5 min).
1H NMR (500 MHz, DMSO-d6): δ
(ppm) = 8.66 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.97 (s, 1H), 7.68 (d, J
= 7.9 Hz, 1H), 7.35 (d, J = 7.9 Hz, 2H), 3.04 (d, J = 10.0 Hz, 2H), 2.69−
2.54 (m, 3H), 2.02 (td, J = 4.4, 8.6 Hz, 1H), 1.75−1.65 (m, (6Hacetate),
8H), 1.60−1.51 (m, 2H), 0.96 (dt, J = 3.5, 8.9 Hz, 2H), 0.82 (dt, J = 3.5,
7.3 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ (ppm) = 174.0
(2Cacetate), 167.5, 150.7, 147.0, 144.6, 140.9, 137.7, 137.2, 127.8 (2C),
127.3 (2C), 127.1, 119.4, 117.9, 46.9 (2C), 42.5, 34.4 (2C), 24.6
(2Cacetate), 8.3 (2C), 7.2.
Hex-5-yn-1-yl 4-Methylbenzenesulfonate (106). To a solution of
hex-5-yn-1-ol 105 (0.84 mL, 7.64 mmol), triethylamine (1.28 mL, 9.17
mmol), and 4-(dimethylamino)pyridine (20 mg, 0.15 mmol) in CH2Cl2
(25 mL) at 0 °C was added p-toluenesulfonyl chloride (1.53 g, 8.02
mmol) in three portions. The reaction mixture was brought to rt. and
stirred for 15 h. Aqueous NaOH (1 N, 15 mL) was added, and the
mixture was vigorously stirred for 15 min at rt. The aqueous phase was
extracted with CH2Cl2. The combined organic fractions were washed
with water, followed by brine, and then dried over Na2SO4, filtered, and
concentrated in vacuo to give the title compound (1.68 g, 88%) as a
yellowish oil. 1HNMR (400MHz, CDCl3): δ (ppm) = 7.69 (2H, J = 8.0,
d), 7.26 (d, J = 8.0 Hz, 2H), 3.96 (t, J = 6.0 Hz, 2H), 2.31 (s, 3H), 2.05−
2.09 (m, 2H), 1.84 (t, J = 4.0 Hz, 1H), 1.65−1.68 (m, 2H), 1.42−1.48
(m, 2H). 13C NMR (100 MHz, CDCl3): δ 144.8, 133.0, 129.9, 127.0,
83.4, 69.9, 69.0, 27.7, 24.2, 21.6, 17.7.
6-Bromohex-1-yne (107). LiBr (1.7 g, 19.6 mmol) was added to a
stirred solution of 106 (1.64 g, 6.52 mmol) in dry DMF (20 mL). After
the exothermic reaction, the mixture was stirred at room temperature for
24 h. Then water (25 mL) was added and the aqueous phase extracted
with Et2O (3 × 25 mL). The collected organic fractions were dried over
Na2SO4, filtered, and concentrated in vacuo. The residue was purified by
flash chromatography using as eluent hexane:ethyl acetate (5:1) to
afford a colorless oil (0.86 g, 82%). 1H NMR (400 MHz, CDCl3): δ
(ppm) = 3.59 (t, J = 6.4, 2H), 2.24 (m, 2H), 1.90−1.98 (m, 3H), 1.66−
1.70 (m, 2H). 13CNMR (100MHz, CDCl3): δ (ppm) = 83.8, 69.2, 45.6,
29.7, 29.4, 19.7.
6-Bromohexan-1-amine Hydrochloride (109). 6-Aminohexanol
108 (0.5 g, 4.27 mmol) was slowly added to a stirring 48% HBr
solution (5.1 mL) at 0 °C, and the resulting mixture was stirred at 80 °C
for 20 h. Themixture was neutralized by adding 2NNaOH (20mL) and
extracted with ethyl acatate (3 × 20 mL). The combined organic
fractions were washed with water (50 mL) followed by brine (50 mL)
and then dried over Na2SO4, filtered, and concentrated in vacuo. The
obtained viscous oil was dissolved in 4MHCl solution in dioxane to give
a sticky solid that was washed with Et2O and then filtered to afford a
yellowish solid (0.55 g, 61%). 1H NMR (400 MHz, MeOD): δ (ppm) =
3.39 (t, J = 4.0 Hz, 2H), 2.86 (t, J = 8.0 Hz, 2H), 1.74−1.82 (m, 2H),
1.59−1.70 (m, 2H), 1.42−1.46 (m, 4H). 13CNMR (100MHz, MeOD):
δ (ppm) = 44.2, 32.8, 32.2, 27.2, 27.0, 25.2.
6-Azidohexan-1-amine (110). To a solution of 109 (0.55 g, 2.54
mmol) in water (25 mL), NaN3 (0.49 g, 7.69 mmol) was added, and the
resulting mixture was heated at 100 °C for 12 h. After cooling, 37%
ammonia solution was added until a basic pH was reached, and the
aqueous phase was extracted with Et2O (3 × 20 mL). The organic
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fractions were collected, dried over Na2SO4, and filtered, and the solvent
removed under vacuum to give a yellow oil (0.29 g, 80%). 1HNMR (400
MHz, CDCl3): δ (ppm) = 3.18 (t, J = 8.0 Hz, 2H), 2.62 (t, J = 4.0 Hz,
2H), 2.15 (br s, 2H), 1.50−1.54 (m, 2H), 1.35−1.40 (m, 2H), 1.29−
1.34 (m, 4H). 13CNMR (100MHz, CDCl3): δ (ppm) = 51.4, 41.8, 33.1,
28.8, 26.6, 26.4.
Ethyl 4-(4-(Piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-
naphthoate (111). To a solution of 3 (0.50 g, 1.57 mmol) in EtOH (50
mL), thionyl chloride (1.37 mL, 18.84 mmol) was carefully added over
30 min at 0 °C. The reaction was allowed to warm up to rt and stirred
overnight. The resulting mixture was quenched by adding 5% NaOH
solution (25 mL). Then the solvent was evaporated under vacuum and
the aqueous residue extracted with ethyl acetate (3 × 20 mL). The
collected organic fractions were dried over Na2SO4, filtered, and the
solvent removed under vacuum. The residue was purified by
chromatography using as eluent CH2Cl2/MeOH/NH4OH (7:3:0.3).
The title compound was obtained as a white solid (0.61 g, 78%). MS
(ESI,m/z) 504 [M+H]+. ESI-HRMS calcd for C31H29F3NO2 504.2150,
found 504.2150 [M + H]+. 1H NMR (400 MHz, MeOD): δ (ppm) =
8.58 (s, 1H), 8.26 (s, 1H), 7.83−7.90 (m, 4H), 7.76−7.79 (m, 1H), 7.69
(d, J = 8.0 Hz, 2H), 7.33−7.37 (m, 4H), 4.35 (q, J = 8.0 Hz, 2H), 3.15−
3.19 (m, 2H), 2.73−2.79 (m, 3H), 1.81−1.84 (m, 2H), 1.65−1.69 (m,
2H), 1.35 (t, J = 4.0 Hz, 3H).
Ethyl 4-(4-(1-(Hex-5-yn-1-yl)piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoate (112). K2CO3 (0.12 g, 0.9
mmol) was added to a solution of 111 (0.15 g, 0.3 mmol) in dry DMF
(15 mL), and the resulting mixture was left stirring for 20 min.
Compound 107 (0.06 g, 0.6 mmol) was subsequently added, and the
reaction mixture was first stirred at rt for 2h and then at 50 °C for 2.5 h.
After cooling down at rt, saturated NaHCO3 solution (15 mL) was
added, and the aqueous phase extracted with ethyl acetate (3 × 20 mL).
The collected organic fractions were dried over Na2SO4, filtered, and the
solvent removed in vacuo. The residue was purified by chromatography
using as eluent CH2Cl2/MeOH/NH4OH (9.5:0.5:0.05). The desired
compound was obtained as a colorless oil (0.16 g, 92%). MS (ESI,m/z)
584 [M + H]+. ESI-HRMS calcd for C37H37F3NO2 584.2783, found
584.2776 [M + H]+. 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.60 (s,
1H), 8.15 (s, 1H), 7.91−7.95 (m, 2H), 7.71−7.76 (m, 2H), 7.67−7.70
(m, 3H), 7.38 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.38 (q, J =
8.0 Hz, 2H), 3.10−3.13 (m, 2H), 2.56−2.59 (m, 1H), 2.40−2.44 (m,
2H), 2.06−2.17 (m, 5H), 1.90−1.99 (m, 4H), 1.65−1.69 (m, 2H),
1.51−1.55 (m, 2H), 1.38 (t, J = 4.0 Hz, 3H). 13C NMR (100 MHz,
CDCl3): δ (ppm) = 166.6, 143.9, 140.5, 137.6, 133.3, 130.6, 130.1,
129.6, 128.0, 127.9, 127.4, 127.1, 127.0, 126.7, 125.9, 84.3, 68.6, 61.3,
58.3, 54.3, 42.3, 33.0, 29.7, 26.5, 25.8, 25.7, 18.4, 14.4.
Ethyl 4-(4-(1-(4-(1-(6-Aminohexyl)-1H-1,2,3-triazol-4-yl)butyl)-
piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate
(113). To a solution of 112 (50 mg, 0.09 mmol) in CH2Cl2:t-
BuOH:H2O (1:1:1) (2 mL), compound 110 was added, followed by
copper(II) sulfate pentahydrate (15 mol %) and sodium ascorbate (45
mol %). The reaction mixture was stirred for 24 h at rt. The solvents
were removed under vacuum and the residue rinsed with 37% ammonia
solution (5 mL) and extracted with ethyl acetate (3 × 8 mL). The
collected organic fractions were dried over Na2SO4, filtered, and the
solvent removed under reduced pressure. The residue was purified by
chromatography using as eluent a gradient of CH2Cl2/MeOH/NH4OH
(from 9.5:0.5:0.05 to 7:3:0.3). The title product was obtained as a white
solid (32 mg, 51%). MS (ESI,m/z) 726 [M + H]+. ESI-HRMS calcd for
C43H51F3N5O2 726.3984, found 726.3995 [M + H]
+. 1H NMR (400
MHz, CDCl3): δ (ppm) = 8.62 (s, 1H), 8.15 (s, 1H), 7.96−7.99 (m,
2H), 7.73−7.76 m, 2H), 7.66−7.70 (m, 3H), 7.38−7.40 (m, 2H), 7.30−
7.33 (m, 2H), 7.21−7.23 (m, 1H), 4.38 (q, J = 8.0 Hz, 2H), 4.23−4.26
(m, 2H), 3.09−3.17 (m, 2H), 2.65−2.71 (m, 6H), 2.39−2.42 (m, 3H),
2.04−2.07 (m, 2H), 1.83−1.88 (m, 6H), 1.58−1.65 (m, 6H), 1.35−1.39
(m, 7H).
4-(4-(1-(4-(1-(6-Aminohexyl)-1H-1,2,3-triazol-4-yl)butyl)-
piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoic
Acid (114). To a solution of 113 (32 mg, 44 μmol) in MeOH (1 mL), a
solution of 0.5M LiOH (1mL) was added and the resulting mixture was
heated at 60 °C and stirred overnight. After cooling, the solvents were
evaporated and the residue purified by preparative HPLC (Rt = 31.08
min). The product was obtained as a white solid by freeze-drying (6.5
mg, 21%). MS (ESI, m/z) 698 [M + H]+. ESI-HRMS calcd for
C41H47F3N5O2 698.3690, found 698.3682 [M + H]
+. 1H NMR (400
MHz, MeOD): δ (ppm) = 8.49 (s, 1H), 8.27 (s, 1H), 7.89−7.94 (m,
4H), 7.70−7.72 (m, 4H), 7.66−7.70 (m, 3H), 7.38 (d, J = 8.0 Hz, 2H),
7.32 (d, J = 8.0 Hz, 2H), 4.30 (t, J = 8.0 Hz, 2H), 3.09−3.12 (m, 2H),
2.79 (t, J = 8.0 Hz, 2H), 2.66−2.70 (m, 3H), 2.46−2.50 (m, 2H), 2.19−
2.25 (m, 2H), 1.81−1.86 (m, 6H), 1.52−1.64 (m, 6H), 1.26−1.33 (m,
4H).
Pharmacological Assays. Procedures for functional assays at the
P2Y14R reported previously were followed.
14,15Ki values were calculated
from IC50 values using the Cheng−Prusoff equation.
30
Fluorescent Ligand Binding. Fluorescent ligand binding experi-
ments were performed using FCM for all the final triazole derivatives.
An initial experiment involved screening of the compounds at a single
concentration (3 μM) to determine the percentage inhibition, followed
by a full concentration−response curve for the more potent compounds.
For FCM binding experiments in hP2Y14R-CHO cells using 4 as
fluorescent tracer,15 CHO cells expressing hP2Y14Rs were grown in 12-
well plates and used for the assay when the cells were 80% confluent.
CHO cells were incubated with a test compound (nonfluorescent
antagonist) for 30 min, followed by continued incubation for 30 min
after the addition of 20 nM of fluorescent antagonist 4. After the
incubation, the cells were prepared for FCM analysis as described below.
Briefly, cells were washed 3 times with ice-cold PBS and detached with
0.2% EDTA, which was neutralized with media after 5 min incubation at
37 °C. Cell suspensions were transferred to polystyrene round-bottom
BD Falcon tubes (BD, Franklin Lakes, NJ), and centrifuged twice at
400g for 5 min. Cells were then suspended in PBS and proceeded to
FCM using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ),
with a 635 nm laser. MFIs were recorded in FL-1 channel in log mode.
All data were analyzed by nonlinear least-squares analysis, and Ki values
were calculated using Prism (GraphPad Software, San Diego, CA) for all
assays.
To quantify the number of receptor-bound ligands, we used
quantitative fluorescence calibration. To convert measured fluorescence
intensity (MFI) values into molecules of equivalent soluble
fluorochrome (MESF) values, we used Quantum Alexa fluor 488
MESF calibration beads and QuickCal program v. 2.3 (Bangs
Laboratories, Inc., Fishers, IN) according to the instructions of the
manufacturer. The detailed procedure is explained in the Supporting
Information (Figure S3).
Compounds 79, 82, 95, and 101 displayed low solubility in DMSO,
and therefore their 5 mM DMSO-solutions were heated to 50 °C for 5
min prior to the dilution step. To confirm the physicochemical stability
of the derivatives, 1H NMR spectra were taken before and after heating,
and no change in the 1H NMR was observed.
Quantification of cAMP Accumulation. cAMP accumulation in cells
was quantified by competitive enzyme-linked immunoassay. Cells were
plated in 12-well plates 24 h before the assay, and 30 min before the
assay the cells were washed with PBS and themediumwas changed to 20
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-
buffered serum-free DMEM. The assays were performed in the presence
of 10 μM rolipram and were initiated by the addition of 30 μM forskolin,
agonist and/or antagonists.14 Incubation was for 15 min at 37 °C and
were terminated by washing the cells twice with ice-cold PBS, and the
cells were lysed using 100 μL of cell lysis buffer (Cell Signaling, Danvers,
MA). Then 50 μL of the cell lysate were used for the quantification of
cAMP using a Cyclic AMP XP assay kit (Cell Signaling, Danvers, MA)
following manufacturer’s instructions.
Molecular Modeling. Homology Model Refinement. Compound
3was built usingMaestro and prepared with the Ligprep module31 using
the OPLS-2005 force field.32 The ligand was docked to the previously
obtained UDP-bound MD-refined hP2Y14R homology model
16 by
means of the Induced Fit Docking (IFD) procedure based on Glide
search algorithm and SP scoring function.33 In particular, a Glide grid
was positioned on the centroid of residues located within 5 Å from the
previously identified cavity.16 TheGlide grid was built using an inner box
of 10 Å × 10 Å × 10 Å and an outer box that extended 20 Å in each
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b00044
J. Med. Chem. 2016, 59, 6149−6168
6165
direction around the inner box. The ligand was docked rigidly, and side
chains within 5 Å of the ligand were refined. The top ranked docking
pose was then subjected to 10 ns of MD simulations and the final
trajectory snapshot of the receptor used as a template to redock
compound 3 and to dock compounds 11 and 65 along with its structural
analogues.
Docking of Compounds 3, 11, and 65. Ligands were built using
Maestro and prepared using the Ligprep module31 and OPLS_2005
force field.32 Molecular docking of ligands to the 3-bound hP2Y14RMD-
refined model was performed by means of the Glide software package34
from the Schrodinger suite, using the XP scoring function.35 The
binding site was centered on the ligand barycenter and a Glide grid was
computed (inner box side = 10 Å; outer box side = 30 Å). The top
ranked docking poses for each ligand were subjected to 30 ns of
membrane MD simulations.
Molecular Dynamics. The setup of the MD simulation was
performed as previously described.16 In brief, the hP2Y14R homology
model was uploaded to the “Orientations of Proteins in Membranes
(OPM)” server36 and a suggested orientation was provided based on the
2MeSADP-bound hP2Y12R orientation (PDB: 4PXZ).
18 The model
was then positioned in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line (POPC) lipid bilayer (70 Å × 70 Å) generated by a grid-based
method using the VMD37Membrane Plugin tool, and overlapping lipids
within 0.6 Å were removed upon combining the protein and the
membrane system. Each protein−membrane system was then solvated
with TIP3P water using the Solvate 1.0 VMD37 Plugin tool and
neutralized by 0.154 M Na+/Cl− counterions.
High-performance computational capabilities of the Biowulf Linux
GPU cluster at the National Institutes of Health, Bethesda, MD (http://
biowulf.nih.gov) were exploited to run MD simulations with periodic
boundary conditions using the Nanoscale Molecular Dynamics
(NAMD) software package38 and the CHARMM36 Force Field.39,40
The ligands were parametrized by analogy using the ParamChem service
(1.0.0) and implementing the CHARMM General Force Field for
organic molecules (3.0.1).41,42 A 10000-step conjugate gradient
minimization was initially performed to minimize steric clashes. The
protein and ligand atoms were kept fixed during an initial 8 ns
equilibration of the lipid and water molecules. Atom constraints were
then removed, and the entire system was allowed to equilibrate. The
temperature was maintained at 300 K using a Langevin thermostat with
a damping constant of 3 ps−1. The pressure was maintained at 1 atm
using a Berendsen barostat. An integration time step of 1 fs was used,
while hydrogen−oxygen bond lengths and hydrogen−hydrogen angles
in water molecules were constrained using the SHAKE algorithm.43
VMD 1.937 was used for trajectory analysis and movie making. Each
structure was simulated for 30 ns without constraints. RMSD plots for
ligand atoms during the 30 ns trajectories were used to compare relative
ligand stability in the binding pocket during the simulation.
Docking of Triazole Analogues. A library of 57 triazole compounds
was designed and screened using the 3-refined P2Y14 model as receptor
template. The binding pose of 3 was set as a constraint for the docking,
including exposure of the positively charged piperidine ring toward the
solvent and 2-naphthoic acid carbonyl interactions with Lys772.60 and
Lys2777.35. Molecular docking of ligands to the hP2Y14R MD-refined
model was performed by means of the Glide package,34 using the SP
scoring function. The ligand binding site was defined as above-
described. Protein interaction sites were calculated by means of the
SiteMap package44 as implemented in the Schrodinger suite on the apo
form of the hP2Y14R MD-refined model by generating at least 15 points
per site with the OPLS_2005 force field.32 The top ranked site was used
to select the compounds according to optimal overlap between
hydrophobic and hydrogen bond donor/acceptor protein sites and
ligand functional groups evaluated by visual inspection.
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Mulrooney, E.; Robichaud, J.; Theŕien, M.; Tranmer, G.; Wang, Z.; Wu,
J.; Black, W. C. The identification of 4,7-disubstituted naphthoic acid
derivatives as UDP-competitive antagonists of P2Y14. Bioorg. Med. Chem.
Lett. 2011, 21, 2836−2839.
(12) Guay, D.; Beaulieu, C.; Belley, M.; Crane, S. N.; DeLuca, J.;
Gareau, Y.; Hamel, M.; Henault, M.; Hyjazie, H.; Kargman, S.; Chan, C.
C.; Xu, L.; Gordon, R.; Li, L.; Mamane, Y.; Morin, N.; Mancini, J.;
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